CA2461202A1 - Lactam-containing compounds and derivatives thereof as factor xa inhibitors - Google Patents

Lactam-containing compounds and derivatives thereof as factor xa inhibitors Download PDF

Info

Publication number
CA2461202A1
CA2461202A1 CA002461202A CA2461202A CA2461202A1 CA 2461202 A1 CA2461202 A1 CA 2461202A1 CA 002461202 A CA002461202 A CA 002461202A CA 2461202 A CA2461202 A CA 2461202A CA 2461202 A1 CA2461202 A1 CA 2461202A1
Authority
CA
Canada
Prior art keywords
phenyl
substituted
cr3r3a
ring
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002461202A
Other languages
French (fr)
Other versions
CA2461202C (en
Inventor
Donald Pinto
Mimi Quan
Michael Orwat
Yun-Long Li
Wei Han
Jennifer Qiao
Patrick Lam
Stephanie Koch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Holdings Ireland ULC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23262376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2461202(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to CA2726702A priority Critical patent/CA2726702A1/en
Publication of CA2461202A1 publication Critical patent/CA2461202A1/en
Application granted granted Critical
Publication of CA2461202C publication Critical patent/CA2461202C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • B65D81/3216—Rigid containers disposed one within the other
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Mechanical Engineering (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The present application describes lactam-containing compounds and derivative s thereof of Formula I: P4-P-M-M4 or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compound s of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Claims (20)

1. A compound of Formula I:

I
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;
M is a 3-10 membered carbocycle or a 4-10 membered heterocycle, consisting of: carbon atoms and 1-3 heteroatoms selected from 0, S(O)p, N, and NZ2;
ring M is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds;
P is fused onto ring M and is a 5, 6, or 7 membered carbocycle or a 5, 6, or 7 membered heterocycle, consisting of: carbon atoms and 1-3 heteroatoms selected from 0, S(O)p, and N;
ring P is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds;
alternatively, ring P is absent and P4 is directly attached to ring M, provided that when ring P is absent, P4 and M4 are attached to the 1,2, 1,3, or 1,4 positions of ring M;
one of P4 and M4 is -Z-A-B and the other -G1-G;
G is a group of Formula IIa or IIb:

ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of:
carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p;
ring D is substituted with 0-2 R and there are 0-3 ring double bonds;
E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and is substituted with 1-2 R;
alternatively, ring D is absent and ring E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl, and ring E is substituted with 1-2 R;
alternatively, ring D is absent and ring E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl, and ring E is substituted with 1 R and with a 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, wherein the 5-6 membered heterocycle is substituted with 0-1 carbonyl and 1-2 R and there are 0-3 ring double bonds;
R is selected from H, C1-4 alkyl, F, Cl, Br, I, OH, OCH3, OCH2CH3, OCH(CH3)2, OCH2CH2CH3, CN, C(=NR8)NR7R9, NHC(=NR8)NR7R9, ONHC(=NR8)NR7R9, NR8CH(=NR7), NH2, NH(C1-3 alkyl), N(C1-3 alkyl)2, C(=NH)NH2, CH2NH2, CH2NH(C1-3 alkyl), CH2N(C1-3 alkyl)2, CH2CH2NH2, CH2CH2NH(C1-3 alkyl), CH2CH2N(C1-3 alkyl)2, (CR8R9)t C(O)H, (CR8R9)t C(O)R2c, (CR8R9)t NR7R8, (CR8R9)t C(O)NR7R8, (CR8R9)t NR7C(O)R7, (CR8R9)t OR3, (CR8R9)t S(O)p NR7R8, (CR8R9)t NR7S(O)p R7, (CR8R9)t SR3, (CR8R9)t S(O)R3, (CR8R9)t S(O)2R3, and OCF3;
alternatively, when 2 R groups are attached to adjacent atoms, they combine to form methylenedioxy or ethylenedioxy;
A is selected from:
C3-10 carbocycle substituted with 0-2 R4, and 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4;
provided that A is other than a dihydro-benzopyran;
B is ; provided that Z and B are attached to different atoms on A and that the A-X-N moiety forms other than a N-N-N group;
provided that B is other than triazolone, quinolone, or isoquinolone, wherein the triazolone, quinolone, and isoquinolone groups are substituted or unsubstituted;
Q1 is selected from C=O and SO2;
ring Q is a 4-8 membered monocyclic or bicyclic ring consisting of, in addition to the N-Q1 group shown, carbon atoms and 0-2 heteroatoms selected from NR4C, 0, S, S(O), and S(O)2, wherein:
0-2 double bonds are present within the ring and the ring is substituted with 0-2 R4a;

alternatively, ring Q is a 4-8 membered monocyclic or bicyclic ring to which another ring is fused, wherein:
the 4-7 membered ring consists of, in addition to the shown amide group, carbon atoms and 0-2 heteroatoms selected from NR4c, O, S, S(O), and S(O)2, and 0-2 double bonds are present within the ring;
the fusion ring is phenyl or a 5-6 membered heteroaromatic consisting of carbon atoms and 1-2 heteroatoms selected from NR4c, O, S, S(O), and S(O)2;
ring Q, which includes the 4-7 membered ring and the fusion ring, is substituted with 0-3 R4a;
alternatively, two non-adjacent atoms of one of the rings of ring Q are bridged with 1-2 atoms selected from:
carbon atoms, NR4c, O, S, S(O), and S(O)2, provided bonds other than O-O, S(O)p-O, S(O)p-S(O)p, N-O, and N-S(O)p are present;
X is absent or is selected from -(CR2R2a)1-4-, -CR2(CR2R2b) (CH2)t-, -C(O)-, -C(=NR1C)-, -CR2 (NR1c R2)-, -CR2(OR2)-, -CR2(SR2)-, -C(O)CR2R2a-, -CR2R2a C(O), -S(O)-, -S(O)2-, -SCR2R2a-, -S(O)CR2R2a-, -S(O)2CR2R2a-, -CR2R2a S(O)-, -CR2R2a S(O)2-, -S(O)2NR2CR2R2a-, -NR2S(O)2-, -CR2R2a NR2S(O)2-, -NR2S(O)2CR2R2a-, -NR2C(O)-, -C(O)NR2CR2R2a-, -NR2C(O)CR2R2a-, -CR2R2a NR2C(O)-, -NR2CR2R2a-, and -OCR2R2a-;
G1 is absent or is selected from (CR3R3a)1-5, (CR3R3a)0-2CR3=CR3(CR3R3a)0-2, (CR3R3a)0-2C.ident.C(CR3R3a)0-2, (CR3R3a)u C(O) (CR3R3a)w, (CR3R3a)u C(O)O(CR3R3a)w, (CR3R3a)u OC(O) (CR3R3a)w, (CR3R3a)u O(CR3R3a)w, (CR3R3a)u N3b(CR3R3a)w, (CR3R3a)u C(O)N3b(CR3R3a)w, (CR3R3a)u N3b C(O) (CR3R3a)w, (CR3R3a)u OC(O)N3b(CR3R3a)w, (CR3R3a)u N3b C(O)O(CR3R3a)w, (CR3R3a)u N3b C(O)N3b(CR3R3a)w, (CR3R3a)u N3b C(S)N3b(CR3R3a)w, (CR3R3a)u S(CR3R3a)w, (CR3R3a)u S(O)(CR3R3a)w, (CR3R3a)u S(O)2(CR3R3a)w, (CR3R3a)u S(O)N3b(CR3R3a)w, (CR3R3a)u N3b S(O)2(CR3R3a)w, (CR3R3a)u S(O)N3b(CR3R3a)w, (CR3R3a)u N3b S(O)2N3b(CR3R3a)w, (CR3R3a)u NR3e(CR3R3a)w, (CR3R3a)u C(O)(CR3R3a)u C(O)(CR3R3a)w, (CR3R3a)u NR3b(CR3R3a)u C(O)NR3b(CR3R3a)w, (CR3R3a)u NR3b C(O)(CR3R3a)u C(O)(CR3R3a)w, (CR3R3a)u C(O)(CR3R3a)u C(O) NR3b (CR3R3a)w, (CR3R3a)u NR3b C(O)(CR3R3a)u C(O)NR3b(CR3R3a)w, (CR3R3a)u S(O)NR3b C(O)(CR3R3a)w.
(CR3R3a)u C(O)NR3b S(O)2(CR3R3a)w, and (CR3R3a)u S(O)NR3b C(O)NR3b CR3R3a)w, wherein a + w total 0, 1, 2, 3, or 4, provided that G1 does not form an N-S, NCH2N, NCH2O, or NCH2S bond with either group to which it is attached;
Z is selected from a bond, -(CR3R3e)1-4-, (CR3R3e) q O(CR3R3e)q1, (CR3R3e)q NR3b(CR3R3e)q1, (CR3R3e) q C(O)(CR3R3e)q1, (CR3R3e)q C(O)O(CR3R3e)q1, (CR3R3e) q OC(O)(CR3R3e)q1, (CR3R3e)q C(O)NR3b(CR3R3e)q1, (CR3R3e) q NR3b C(O)(CR3R3e)q1, (CR3R3e)q OC(O)O(CR3R3e)q1, (CR3R3e) q OC(O)NR3b (CR3R3e)q1, (CR3R3e) q NR3b C(O)O(CR3R3e)q1, (CR3R3e) q NR3b C(O)NR3b(CR3R3e)q1, (CR3R3e) q C(O)(CR3R3e)q C(O)(CR3R3e)q1, (CR3R3e) q NR3b (CR3R3e)q C(O)NR3b (CR3R3e)q1, (CR3R3e) q NR3b C(O)(CR3R3e)q C(O)(CR3R3e)q1, (CR3R3e) q C(O)(CR3R3e)q C(O)NR3b(CR3R3e)q1, (CR3R3e) q NR3b C(O)(CR3R3e)q C(O)NR3b(CR3R3e)q1, (CR3R3e) q S(CR3R3e)q1, (CR3R3e)q S(O)(CR3R3e)q1, (CR3R3e)q S(O)2(CR3R3e)q1, (CR3R3e)q SO2NR3b(CR3R3e)q1, (CR3R3e)q NR3b SO2(CR3R3e)q1, (CR3R3e)q S(O)NR3b C(O)(CR3R3e)q1, (CR3R3e)q C(O)NR3b S(O)2 (CR3R3e)q1, and (CR3R3e)q NR3b SO2NR3b(CR3R3e)q1, wherein q + q1 total 0, 1, 2, 3, or 4, provided that Z does not form a N-S, NCH2N, NCH2O, or NCH2S bond with either group to which it is attached;
provided that B-A-Z form other than a pyridone-phenyl-CH2, pyridone-pyridyl-CH2, or pyridone-pyrimidyl-CH2, wherein the pyridone, phenyl, pyridyl, and pyrimidyl groups are substituted or unsubstituted;
Z2 is selected from H, S(O)2NHR3b, C(O)R3b, C(O)NHR3b, C(O)OR3f, S(O)R3f, S(O)2R3f, C1-6 alkyl substituted with 0-2 R1a, C2-6 alkenyl substituted with 0-2 R1a, C2-6 alkynyl substituted with 0-2 R1a, -(C0-4 alkyl)-C3-10 carbocycle substituted with 0-3 R1a, and -(C0-4 alkyl)-5-10 membered heterocycle substituted with 0-3 R1a and consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p;
R1a, at each occurrence, is selected from H, -(CR3R3a)R-R1b.
-(CR3R3a)R-CR3R1b R1b, -(CR3R3a)r-O-(CR3R3a)R-R1b, -C2-6 alkenylene-R1b, -C2-6 alkynylene-R1b, -(CR3R3a)r-C(=NR1b)NR3R1b, NR3CR3R3a R1c, OCR3R3a R1c, SCR3R3a R1c, NR3(CR3R3a)2(CR3R3a)t R1b, C(O)NR2(CR3R3a)2(CR3R3a)t R1b, CO2(CR3R3a)2(CR3R3a)t R1b, O(CR3R3a)2(CR3R3a)t R1b, S(CR3R3a)2(CR3R3a)t R1b, S(O)p(CR3R3a)r R1d, O(CR3R3a)r R1d, NR3(CR3R3a)r R1d, OC(O)NR3(CR3R3a)r R1d, NR3C(O)NR3(CR3R3a)r R1d, NR3C(O)O(CR3R3a)r R1d, and NR3C(O)(CR3R3a)r R1d, provided that R1a forms other than an N-halo, N-S, O-O, or N-CN
bond;
alternatively, when two R1a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5-7 membered ring consisting of:
carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p, this ring being substituted with 0-2 R4b and 0-3 ring double bonds;
R1b is selected from H, C1-3 alkyl, F, Cl, Br, I, -CN, -NO2, -CHO, (CF2)r CF3, (CR3R3a)r OR2, NR2R2a, C(O)R2b, CO2R2b, OC(O)R2, (CF2)r CO2R2a, S(O)p R2b, NR2(CH2)r OR2, C(=NR2c)NR2R2a, NR2C(O)R2b, NR2C(O)NHR2, NR2C(O)2R2a, OC(O)NR2R2a, C(O)NR2R2a, C(O)NR2(CH2)r OR2, SO2NR2R2a, NR2SO2R2, C(O)NR2SO2R2, C3-6 carbocycle substituted with 0-2 R4b, and 5-10 membered heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b, provided that R1b forms other than an O-O, N-halo, N-S, or N-CN bond;
R1c is selected from H, CH(CH2OR2)2, C(O)R2c, C (O)NR2R2a, S(O)R2, S(O)2R2, and SO2NR2R2a;
R1d is selected from C3-6 carbocycle substituted with 0-2 R4b and 5-10 membered heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b, provided that R1d forms other than an N-S
bond;

R2, at each occurrence, is selected from H, CF3, C1-6 alkyl, benzyl, -(CH2)r-C3-10 carbocycle substituted with 0-2 R4b, and -(CH2)r-5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, 0, and S(0)p, and substituted with 0-2 R4b R2a, at each occurrence, is selected from H, CF3, C1-6 alkyl, benzyl, -(CH2)r-C3-10 carbocycle substituted with 0-2 R4b, and -(CH2)r-5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)p;
R2b, at each occurrence,, is selected from CF3, C1-4 alkoxy substituted with 0-2 R4b, C1-6 alkyl substituted with O-2 R4b, -(CH2)r-C3-10 carbocycle substituted with 0-2 R4b, and -(CH2)r-5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b R2c, at each occurrence, is selected from CF3, OH, C1-4 alkoxy, C1-6 alkyl, -(CH2)r-C3-10 carbocycle substituted with 0-2 R4b, and -(CH2)r-5-10 membered heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
R3, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl, and phenyl;
R3a, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl, and phenyl;
alternatively, R3 and R3a, together with the nitrogen atom to which they are attached, combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring consisting of: carbon atoms, the nitrogen atom to which R3 and R3a are attached, and 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)p;
R3b, at each occurrence, is selected from H, C1-6 alkyl substituted with 0-2 R1a, C2-6 alkenyl substituted with 0-2 R1a, C2-6 alkynyl substituted with 0-2 R1a, -(C0-4 alkyl)-5-10 membered carbocycle substituted with 0-3 R1a, and -(C0-4 alkyl)- 5-10 membered heterocycle substituted with 0-3 R1a and consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p;
R3c, at each occurrence, is selected from CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl, and phenyl;

R3d, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C1-4 alkyl-phenyl, and C(=O)R3c;
R3e, at each occurrence, is selected from H, SO2NHR3, SO2NR3R3, C(O)R3, C(O)NHR3, C(O)OR3f, S(O)R3f, S(O)2R3f, C1-6 alkyl substituted with 0-2 R1a, C2-6 alkenyl substituted with 0-2 R1a, C2-6 alkynyl substituted with 0-2 R1a, -(C0-4 alkyl)-5-10 membered carbocycle substituted with 0-3 R1a, and -(C0-4 alkyl)-5-10 membered heterocycle substituted with 0-3 R1a and consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p;
R3f, at each occurrence, is selected from: C1-6 alkyl substituted with 0-2 R1a, C2-6 alkenyl substituted with 0-2 R1a, C2-6 alkynyl substituted with 0-2 R1a, -(C0-4 alkyl)-5-10 membered carbocycle substituted with 0-3 R1a, and -(C0-4 alkyl)-5-10 membered heterocycle substituted with 0-3 R1a and consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p;
R4, at each occurrence, is selected from H, =O, (CR3R3a)r OR2, F, Cl, Br, I, C1-4 alkyl, (CR3R3a)r CN, (CR3R3a)r NO2. (CR3R3a)r NR2R2a, (CR3R3a)r C(O)R2c, (CR3R3a)r NR2C(O)R2b, (CR3R3a)r C(O)NR2R2a, (CR3R3a)r NR2C(O)NR2R2a, (CR3R3a)r C(=NR2)NR2R2a, (CR3R3a)r C(=NS(O)2R5)NR2R2a, (CR3R3a)r NHC(=NR2)NR2R2a, (CR3R3a)r C(O)NHC(=NR2)NR2R2a, (CR3R3a)r SO2NR2R2a, (CR3R3a)r NR2SO2NR2R2a, (CR3R3a)r NR2SO2-C1-4 alkyl, (CR3R3a)r NR2SO2R5, (CR3R3a)r S(O)p R5a, (CR3R3a)r(CF2)r CF3, NHCH2R1c, OCH2R1c, SCH2R1c, NH(CH2)2(CH2)t R1b, O(CH2)2(CH2)t R1b, S(CH2)2(CH2)t R1b, (CR3R3a)r-5-6 membered carbocycle substituted with 0-1 R5, and a (CR3R3a)r-5-6 membered heterocycle consisting of:
carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5;
R4a, at each occurrence, is selected from H, =O, (CR3R3a)r OR2, (CR3R3a)r F, (CR3R3a)r Br, (CR3R3a)r Cl, C1-4 alkyl, (CR3R3a)r CN, (CR3R3a)r NO2, (CR3R3a)r NR2R2a, (CR3R3a)r C(O)R2c, (CR3R3a) r NR2C (O) R2b, (CR3R3a)r C(O)NR2R2a, (CR3R3a) r N=CHOR3, (CR3R3a)r C(O)NH(CH2)2NR2R2a, (CR3R3a)r NR2C(O)NR2R2a, (CR3R3a)r C(=NR2)NR2R2a, (CR3R3a)r NHC(=NR2)NR2R2a, (CR3R3a)r SO2NR2R2a, (CR3R3a)r NR2SO2NR2R2a, (CR3R3a)r NR2SO2-C1-4 alkyl, (CR3R3a)r C(O)NHSO2-C1-4 alkyl, (CR3R3a)NR2SO2R5, (CR3R3a)r S(O)p R5a, (CR3R3a)r(CF2)r CF3, (CR3R3a)r-5-6 membered carbocycle substituted with 0-1 R5, and a (CR3R3a)r-5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5;
R4b, at each occurrence, is selected from H, =O, (CH2)r OR3, (CH2)r F, (CH2)r Cl, (CH2)r Br, (CH2)r I, C1-4 alkyl, (CH2)r CN. (CH2)r NO2, (CH2)r NR3R3a, (CH2)r C(O)R3, (CH2)r C(O)OR3c, (CH2)r NR3C(O)R3a, (CH2)r-C(O)NR3R3a, (CH2)r NR3C(O)NR3R3a, (CH2)r-C(=NR3)NR3R3a, (CH2)r NR3C(=NR3)NR3R3a, (CH2)r SONR3R3a, (CH2)r NR3SO2NR3R3a, (CH2)r NR3SO2-C1-4 alkyl, (CH2)r NR3SO2CF3, (CH2)r NR3SO2-phenyl, (CH2)r S(O)p CF3, (CH2)r S(O)p-C1-4 alkyl, (CH2)r S(O)p-phenyl, and (CH2)r(CF2)r CF3:
R4c, at each occurrence, is selected from H, C1-4 alkyl (CR3R3a) r1OR2, (CR3R3a) r1F, (CR3R3a) r1Br, (CR3R3a) r1Cl, (CR3R3a) r1CN, (CR3R3a)r1NO2, (CR3R3a)r1NR2R2a, (CR3R3a) r C(O)R2c, (CR3R3a)r1NR2C(O)R2b, (CR3R3a) r C (O) NR2R2a, (CR3R3a) r1N=CHOR3, (CR3R3a) r C(O)NH(CH2)2NR2R2a, (CR3R3a)r1NR2C(O)NR2R2a, (CR3R3a) r1C (=NR2) NR2R2a, (CR3R3a) r1NHC (=NR2) NR2R2a, (CR3R3a) r SO2NR2R2a, (CR3R3a)r1NR2SO2NR2R2a, (CR3R3a) r1NR2SO2-C1-4 alkyl, (CR3R3a) r C(O)NHSO2-C1-4 alkyl, (CR3R3a)r1NR2SOR5, (CR3R3a) r S(O)p R5a, (CR3R3a)r(CF2)r CF3, (CR3R3a) r-5-6 membered carbocycle substituted with 0-1 R5, and a (CR3R3a)r-5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5;

R5, at each occurrence, is selected from H, C1-6 alkyl, =O, (CH2)r OR3, F, Cl, Br, I, -CN, NO2, (CH2)r NR3R3a, (CH2)r C(O)R3,(CH2)r C(O)OR3C, (CH2)r NR3C(O)R3a, (CH2)r C(O)NR3R3a, (CH2)r NR3C(O)NR3R3a, (CH2)r CH(=NOR3d), (CH2)r C(=NR3)NR3R3a, (CH2)r NR3C(=NR3)NR3R3a, (CH2)r SO2NR3R3a, (CH2)r NR3SO2NR3R3a, (CH2)r NR3SO2-C1-4 alkyl, (CH2)r NR3SO2CF3, (CH2)r NR3SO2-phenyl, (CH2)r S(O)p CF3, (CH2)r S(O)p-C1-4 alkyl, (CH2)r S(O)p-phenyl, (CF2)r CF3, phenyl substituted with 0-2 R6, naphthyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6;

R5a, at each occurrence, is selected from C1-6 alkyl, (CH2)r OR3, (CH2)r NR3R3a, (CH2)r C(O)R3, (CH2)r C(O)OR3c, (CH2)r NR3C(O)R3a, (CH2)r C(O)NR3R3a, (CF2)r CF3, phenyl substituted with 0-2 R6, naphthyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6, provided that R5a does not form a S-N or S(O)p-C(O) bond;
R6, at each occurrence, is selected from H, OH, (CH2)r OR2, halo, C1-4 alkyl, CN, NO2, (CH2)r NR2R2a, (CH2)r C(O)R2b, NR2C(O)R2b, NR2C(O)NR2R2a, C(=NH)NH2, NHC(=NH)NH2, SO2NR2R2a, NR2SO2NR2R2a, and NR2SO2C1-4 alkyl;
R7, at each occurrence, is selected from H, OH, C1-6 alkyl, C1-6 alkyl-C(O)-, C1-6 alkyl-O-, (CH2)n-phenyl, C1-4 alkyl-OC(O)-, C6-10 aryl-O-, C6-10 aryl-OC(O)-, C6-10 aryl-CH2-C(O)-, C1-4 alkyl-C(O)O-C1-4 alkyl-OC(O)-, C6-10 aryl-C(O)O-C1-4 alkyl-OC(O)-, C1-6 alkyl-NH2-C(O)-, phenyl-NH2-C(O)-, and phenyl-C1-4 alkyl-C(O)-;
R8, at each occurrence, is selected from H, C1-6 alkyl, and (CH2)n-phenyl;
alternatively, R7 and R8, when attached to the same nitrogen, combine to form a 5-10 membered heterocyclic ring consisting of carbon atoms and 0-2 additional heteroatoms selected from the group consisting of N, O, and S(O)p;
R9, at each occurrence, is selected from H, C1-6 alkyl, and (CH2)n-phenyl;~~

n, at each occurrence, is selected from 0, 1, 2, and 3;
p, at each occurrence, is selected from 0, 1, and 2;
r, at each occurrence, is selected from 0, 1, 2, 3, 4, 5, and 6;
r1, at each occurrence, is selected from 1, 2, 3, 4, 5, and 6;
t, at each occurrence, is selected from 0, 1, 2, and 3;
and, provided that when:
(a) ring M is phenyl and is substituted 1,2 by M4 and P4 and G1 is present, then Z-A is other than NHC(O)-thienyl, NHCH2-thienyl, NHC(O)-benzothienyl, and NHCH2-benzothienyl; and, (b) B is 2-oxo-1-pyrrolidinyl and rings P-M are 1,7-dihydro-2-methyl-6H-purin-6-one, then G-G1 is other then unsubstituted phenyl.
2. A compound according to Claim 1, wherein; the compound is of Formula II:
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;

ring M, including P1, P2, M1, and M2, is a 5, 6, or 7 membered carbocycle or a 5, 6, or 7 membered heterocycle, consisting of: carbon atoms and 1-3 heteroatoms selected from O, S(O)p, N, and NZ2;
ring M is substituted with 0-2 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds;
ring P, including P1, P2, and P3, is a 5 or 6 membered aromatic heterocycle, consisting of: carbon atoms and 1-3 heteroatoms selected from O, S(O)p, and N;
alternatively, ring P, including P1, P2, and P3, is a 5 or 6 membered dihydro-aromatic heterocycle, consisting of:
carbon atoms and 1-3 heteroatoms selected from O, S(O)p, and N;
ring P is substituted with 0-2 R1a;
one of P4 and M4 is -Z-A-B and the other -G1-G;
G is a group of Formula IIa or IIb:
ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of:
carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p;
ring D is substituted with 0-2 R and there are 0-3 ring double bonds;

E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and is substituted with 1-2 R;
alternatively, ring D is absent, and ring E is selected from phenyl, pyridyl, pyrimidyl, and thienyl, and ring E is substituted with 1-2 R;
alternatively, ring D is absent, ring E is selected from phenyl, pyridyl, and thienyl, and ring E is substituted with 1 R and substituted with a 5 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, wherein the 5 membered heterocycle is substituted with 0-1 carbonyl and 1-2 R and there are 0-3 ring double bonds;
R is selected from H, C1-4 alkyl, F, Cl, OH, OCH3, OCH2CH3, OCH(CH3)2, CN, C(=NH)NH2, C(=NH)NHOH, C(=NH)NHOCH3, NH2, NH(C1-3 alkyl), N(C1-3 alkyl)2, C(=NH)NH2, CH2NH2, CH2NH(C1-3 alkyl), CH2N(C1-3 alkyl)2, (CR8R9)t NR7R8, C(O)NR7R8, CH2C(O)NR7R8, S(O)p NR7R8, CH2S(O)p NR7R8, SO2R3, and OCF3;
alternatively, when 2 R groups are attached to adjacent atoms, they combine to form methylenedioxy or ethylenedioxy;
A is selected from:
C5-10 carbocycle substituted with 0-2 R4, and 5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4;
provided that A is other than a dihydro-benzopyran;

B is provided that Z and B are attached to different atoms on A and that the A-X-N moiety forms other than a N-N-N group;
provided that B is other than triazolone, quinolone, or isoquinolone, wherein the triazolone, quinolone, and isoquinolone groups are substituted or unsubstituted;
Q1 is selected from C=O and SO2;
ring Q is a 4-7 membered monocyclic or tricyclic ring consisting of, in addition to the N-Q1 group shown, carbon atoms and 0-2 heteroatoms selected from NR4c, O, S, S(O), and S(O)2, wherein:
0-2 double bonds are present within the ring and the ring is substituted with 0-2 R4a;
alternatively, ring Q is a 4-7 membered ring to which another ring is fused, wherein:
the 4-7 membered ring consists of, in addition to the shown amide group, carbon atoms and 0-2 heteroatoms selected from NR4c, O, S, S(O), and S(O)2 and 0-1 double bonds are present within the ring;
the fusion ring is phenyl or a 5-6 membered heteroaromatic consisting of carbon atoms and 1-2 heteroatoms selected from NR4c, O, and S;
ring Q, which includes the 4-7 membered ring and the fusion ring, is substituted with 0-3 R4a;
X is absent or is selected from -(CR2R2a)1-4-, -C(O)-, -C(O)CR2R2a-, -CR2R2a C(O), -S(O)2-, -S(O)2CR2R2a-, -CR2R2a S(O)2-, -NR2S(O)2-, -NR2CR2R2a-, and -OCR2R2a-;

Z is selected from a bond, CH2, CH2CH2, CH2O, OCH2, C(O), NH, CH2NH, NHCH2, CH2C(O), C(O)CH2, C(O)NH, NHC(O), NHC(O)CH2C(O)NH, S(O)2, CH2S(O)2, S(O)2(CH2), SO2NH, and NHSO2, provided that Z does not form a N-S, NCH2N, NCH2O, or NCH2S bond with either group to which it is attached;
Z2 is selected from H, C1-4 alkyl, phenyl, benzyl, C(O)R3b, S(O)R3f, and S(O)2R3f;
R1a is selected from H, -(CH2)r-R1b, -(CH(CH3))r-R1b, -(C-(CH3)2)r-R1b, NHCH2R1c, OCH2R1c, SCH2R1c, NH(CH2)2(CH2)t R1b, and O(CH2)2(CH2)t R1b, provided that R1a forms other than an N-halo, N-S, or N-CN bond;
alternatively, when two R1a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5-7 membered ring consisting of:
carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p, this ring being substituted with 0-2 R4b and 0-3 ring double bonds;
R1b is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, F, Cl, Br, I, -CN, -CHO, CF3, OR2, NR2R2a, C(O)R2b, CO2R2b, OC(O)R2, CO2R2a, S(O)p R2, NR2(CH2)r OR2, NR2C(O)R2b, NR2C(O)NHR2, NR2C(O)2R2a, OC(O)NR2R2a, C(O)NR2R2a, C(O)NR2(CH2)r OR2, SO2NR2R2a, NR2SO2R2, C5-6 carbocycle substituted with 0-2 R4b, and 5-6 membered heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b, provided that R1b forms other than an O-O, N-halo, N-S, or N-CN bond;

R1c is selected from H, CH(CH2OR2)2, C(O)R2c, C(O)NR2R2a, S(O)R2, S(O)2R2, and SO2NR2R2a;
R2, at each occurrence, is selected from H, CF3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl, C5-6 carbocycle substituted with 0-2 R4b, a C5-6 carbocyclic-CH2-group substituted with 0-2 R4b, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
R2a, at each occurrence, is selected from H, CF3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl, C5-6 carbocycle substituted with 0-2 R4b, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted With 0-2 R4b;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)p;
R2b, at each occurrence, is selected from CF3, C1-4 alkoxy, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl, C5-6 carbocycle substituted with 0-2 R4b, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
R2c, at each occurrence, is selected from CF3, OH, C1-4 alkoxy, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl, C5-6 carbocycle substituted with 0-2 R4b, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
R3, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, and phenyl;
R3a, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, and phenyl;
alternatively, R3 and R3a, together with the nitrogen atom to which they are attached, combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring consisting of: carbon atoms and the nitrogen atom to which R3 and R3a are attached;
R3c, at each occurrence, is selected from CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, and phenyl;
R3d, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2-phenyl, CH2CH2-phenyl, and C(=O)R3c;
R4, at each occurrence, is selected from H, =O, OR2, CH2OR2, (CH2)2OR2, F, Cl, Br, I, C1-4 alkyl, -CN, NO2, NR2R2a,~~

CH2NR2R2a, (CH2)2NR2R2a, C(O)R2c, NR2C(O)R2b, C(O)NR2R2a, SO2NR2R2a, S(O)p R5a, CF3, CF2CF3, 5-6 membered carbocycle substituted with 0-1 R5, and a 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5;
R4a, at each occurrence, is selected from H, =O, CH2OR2, OR2, CH2F, F, CH2Br, Br, CH2Cl, Cl, C1-4 alkyl, CH2-CN, -CN, CH2NO2, NO2, CH2NR2R2a, NR2R2a, CH2-C(O)R2c, C(O)R2c, NR2C(O)R2b, (CH2)r C(O)NR2R2a, NR2C(O)NR2R2a, (CH2)r SO2NR2R2a, NR2SO2NR2R2a, NR2SO2-C1-4 alkyl, NR2SO2R5, (CH2)r S(O)p R5a, CH2CF3, CF3, CH2-5-6 membered carbocycle substituted with 0-1 R5, 5-6 membered carbocycle substituted with 0-1 R5, and a CH2-5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5, and 5-6 membered heterocycle consisting of:
carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5;
R4b, at each occurrence, is selected from H, =O, OR3, CH2OR3, F, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, -CN, NO2, NR3R3a, CH2NR3R3a, C(O)R3, CH2-C(O)R3, C(O)OR3c, CH2C(O)OR3c, NR3C(O)R3a, CH2NR3C(O)R3a, C(O)NR3R3a, CH2C(O)NR3R3a, NR3C(O)NR3R3a, CH2NR3C(O)NR3R3a, C(=NR3)NR3R3a, CH2C(=NR3)NR3R3a, NR3C(=NR3)NR3R3a, CH2NR3C(=NR3)NR3R3a, SO2NR3R3a, CH2SO2NR3R3a, NR3SO2NR3R3a, CH2NR3SO2NR3R3a, NR3SO2-C1-4 alkyl, CH2NR3SO2-C1-4 alkyl, NR3SO2CF3, CH2NR3SO2CF3, NR3SO2-phenyl, CH2NR3SO2-phenyl, S(O)p CF3, CH2S(O)p CF3, S(O)p-C1-4 alkyl, CH2S(O)p-C1-4 alkyl, S(O)p-phenyl, CH2S(O)p-phenyl, CF3, and CH2-CF3;
R4c, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, CH2OR2, CH2F, CH2Br, CH2Cl, CH2CN, CH2NO2, CH2NR2R2a, C(O)R2c, CH2C(O)R2c, CH2NR2C(O)R2b, C(O)NR2R2a, CH2C(O)NR2R2a, CH2NR2C(O)NR2R2a, SO2NR2R2a, CH2SO2NR2R2a, CH2NR2SO2NR2R2a, CH2NR2SO2-C1-4 alkyl, C(O)NHSO2-C1-4 alkyl, CH2C(O)NHSO2-C1-4 alkyl, CH2NR2SO2R5, S(O)p R5a, CH2S(O)p R5a, CF3, CH2CF3, 5-6 membered carbocycle substituted with 0-1 R5, CH2-5-6 membered carbocycle substituted with 0-1 R5, 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5, and a CH2-5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5;
R5, at each occurrence, is selected from H, =O, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, OR3, CH2OR3, F, Cl, -CN, NO2, NR3R3a, CH3NR3R3a, C(O)R3, CH2C(O)R3, C(O)OR3C, CH2C(O)OR3C, NR3C(O)R3a, C(O)NR3R3a, NR3C(O)NR3R3a, CH(=NOR3d), C(=NR3)NR3R3a, NR3C(=NR3)NR3R3a, SO2NR3R3a, NR3SO2NR3R3a, NR3SO2-C1-4 alkyl, NR3SO2CF3, NR3SO2-phenyl, S(O)p CF3, S(O)p-C1-4 alkyl, S(O)p-phenyl, CF3, phenyl substituted with 0-2 R6, naphthyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6; and, R6, at each occurrence, is selected from H, OH, OR2, F, C1, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, CN, NO2, NR2R2a, CH2NR2R2a, C (O)R2b, CH2C (O) R2b, NR2C (O) R2b, NR2C (O)NR2R2a, C (=NH)NH2, NHC (=NH)NH2, SO2NR2R2a, NR2SO2NR2R2a, and NR2SO2C1-4 alkyl.
3. A compound according to Claim 2, wherein;
ring M is substituted with 0-2 R1a and is selected from the group:
ring P, including P1, P2, P3, and P4 is selected from group:
one of P4 and M4 is -Z-A-B and the other -G1-G;
G is selected from the group:
G1 is absent or is selected from (CR3R3a)1-3, (CR3R3a)u C(O)(CR3R3a)w, (CR3R3a)u O(CR3R3a)w, (CR3R3a)u NR3b(CR3R3a)w, (CR3R3a)u C(O)NR3b(CR3R3a)w, (CR3R3a)u NR3b C(O)(CR3R3a)w, (CR3R3a)u NR3b C(O)(CR3R3a)u C(O)NR3b(CR3R3a)w, (CR3R3a)u S(CR3R3a)w, (CR3R3a)u S(O)(CR3R3a)w, (CR3R3a)u S(O)2(CR3R3a)w, (CR3R3a)u S(O)NR3b(CR3R3a)w, (CR3R3a)u NR3b S(O)2(CR3R3a)w, and (CR3R3a)u S(O)2NR3b(CR3R3a)w, wherein u + w total 0, 1, or 2, provided that G1 does not form a N-S, NCH2N, NCH2O, or NCH2S bond with either group to which it is attached;

A is selected from one of the following carbocyclic and heterocyclic groups which are substituted with 0-2 R4;
phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thienyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolinyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;
B is provided that Z and B are attached to different atoms on A;
provided that B is other than triazolone, quinolone, or isoquinolone, wherein the triazolone, quinolone, and isoquinolone groups are substituted or unsubstituted;
Q1 is selected from C=O and SO2;
ring Q is a 5-7 membered ring consisting of, in addition to the N-Q1 group shown, carbon atoms and 0-2 heteroatoms selected from NR4c, O, S, S(O), and S(O)2, wherein:
0-2 double bonds are present within the ring and the ring is substituted with 0-2 R4a;
alternatively, ring Q is a 5-7 membered ring to which another ring is fused, wherein:

the 5-7 membered ring consists of, in addition to the shown amide group, carbon atoms and 0-2 heteroatoms selected from NR4c, O, S, S(O), and S(O)2, and 0-1 double bonds are present within the ring;
the fusion ring is phenyl or a 5-6 membered heteroaromatic consisting of carbon atoms and 1-2 heteroatoms selected from NR4c, O, and S;
ring Q, which includes the 5-7 membered ring and the fusion ring, is substituted with 0-3 R4a;
R1a is selected from H, R1b, CH(CH3)R1b, C(CH3)2R1b, CH2R1b, and CH2CH2R1b, provided that R1a forms other than an N-halo, N-S, or N-CN bond;
alternatively, when two R1a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5-6 membered ring consisting of:
carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p, this ring being substituted with 0-2 R4b and 0-3 ring double bonds;
R1b is selected from H, CH3, CH2CH3, F, Cl, Br, -CN, -CHO, CF3, OR2, NR2R2a, C(O)R2b, CO2R2b, OC(O)R2, CO2R2a, S(O)p R2, NR2(CH2)r OR2, NR2C(O)R2b, C(O)NR2R2a, SO2NR2R2a, NR2SO2R2, phenyl substituted with 0-2 R4b, and 5-6 membered aromatic heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b, provided that R1b forms other than an O-O, N-halo, N-S, or N-CN bond;
R2, at each occurrence, is selected from H, CF3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, phenyl substituted with 0-2 R4b, a benzyl substituted with 0-2 R4b, and~~

a 5-6 membered aromatic heterocycle consisting of:
carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
R2a, at each occurrence, is selected from H, CF3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, phenyl substituted with 0-2 R4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)p;
R2b, at each occurrence, is selected from CF3, C1-4 alkoxy, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, phenyl substituted with 0-2 R4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
R2c, at each occurrence, is selected from CF3, OH, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, phenyl substituted with 0-2, R4b, and 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;~~

R4, at each occurrence, is selected from H, CH2OR2, (CH2)2OR2, OR2, F, Cl, Br, I, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, -CN, NO2, NR2R2a, CH2NR2R2a, (CH2)2NR2R2a, C(O)R2c, NR2C(O)R2b, C(O)NR2R2a, SO2NR2R2a, CF3, and CF2CF3;
R4a, at each occurrence, is selected from H, =O, CH2OR2, OR2, F, Br, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, -CN, NO2, CH2NR2R2a, NR2R2a, C(O)R2c, NR2C(O)R2b, C(O)NR2R2a, NR2C(O)NR2R2a, SO2NR2R2a, and -CF3;
R4b, at each occurrence, is selected from H, =O, OR3, CH2OR3, F, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, -CN, NO2, NR3R3a, CH2NR3R3a, C(O)R3, CH2-C(O)R3, C(O)OR3c, CH2-C(O)OR3c, NR3C(O)R3a, CH2NR3C(O)R3a, C(O)NR3R3a, CH2-C(O)NR3R3a, SO2NR3R3a, CH2SO2NR3R3a, NR3SO2-C1-4 alkyl, CH2NR3SO2-C1-4 alkyl, NR3SO2-phenyl, CH2NR3SO2-phenyl, S(O)p CF3, CH2S(O)p CF3, S(O)p-C1-4 alkyl, CH2S(O)p-C1-4 alkyl, S(O)p-phenyl, CH2S(O)p-phenyl, and CF3;
R4c, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, CH2OR2, CH2F, CH2Br, CH2Cl, CH2CN, CH2NO2, CH2NR2R2a, C(O)R2c, CH2C(O)R2c, CH2NR2C(O)R2b, C(O)NR2R2a, CH2C(O)NR2R2a, SO2NR2R2a, CH2SO2NR2R2a, S(O)p R5a, CH2S(O)p R5a, CF3, phenyl substituted with 0-1 R5, and benzyl substituted with 0-1 R5;

R5, at each occurrence, is selected from H, =O, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, OR3, CH2OR3, F, Cl, -CN, NO2, NR3R3a, CH2NR3R3a, C(O)R3, CH2C(O)R3, C(O)OR3c, CH2C(O)OR3c, NR3C(O)R3a, C(O)NR3R3a, SO2NR3R3a, NR3SO2-C1-4 alkyl, NR3SO2CF3, NR3SO2-phenyl, S(O)p CF3, S(O)p-C1-4 alkyl, S(O)p-phenyl, CF3, phenyl substituted with 0-2 R6, naphthyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6; and, R6, at each occurrence, is selected from H, OH, OR2, F, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, -CN, NO2, NR2R2a, CH2NR2R2a, C(O)R2b, CH2C(O)R2b, NR2C(O)R2b, SO2NR2R2a, and NR2SO2C1-4 alkyl.
4. A compound according to Claim 3, wherein;
ring M is substituted with 0-2 R1a and is selected from the group:
ring P, including P1, P2, P3, and P4 is selected from group:

one of P4 and M4 is -A-B and the other -G;
G is selected from the group:
G1 is absent or is selected from CH2, CH2CH2, CH2O, OCH2, NH, CH2NH, NHCH2, CH2C (O), C(O) CH2, C(O) NH, NHC(O), CH2S(O)2, S(O)2(CH2), SO2NH, and NHSO2, provided that G1 does not form a N-S, NCH2N, NCH2O, or NCH2S bond with either group to which it is attached;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4;
B ; provided that Z and B are attached to different atoms on A;
provided that B is other than triazolone, quinolone, or isoquinolone, wherein the triazolone, quinolone, and isoquinolone groups are substituted or unsubstituted;
Q1 is selected from C=O and SO2;
ring Q is a 6-7 membered ring consisting of, in addition to the N-Q1 group shown, carbon atoms and 0-1 heteroatoms selected from NR4C, O, S, S(O), and S (O) 2, wherein:
0-2 double bonds are present within the ring and the ring is substituted with 0-2 R4a;

alternatively, ring Q is a 5-7 membered ring to which another ring is fused, wherein:
the 5-7 membered ring consists of, in addition to the shown amide group, carbon atoms and 0-1 heteroatoms selected from NR4C, O, S, S(O), and S(O)2, and 0-1 double bonds are present within the ring;
the fusion ring is phenyl;
ring Q, which includes the 5-7 membered ring and the fusion ring, is substituted with 0-2R4a;
R1a is selected from H, R1b, C (CH3) 2R1b, and CH2R1b, provided that R1a forms other than an N-halo, N-S, or N-CN bond;
R1b is selected from CH3, CH2CH3, F, C1, Br, -CN, CF3, OR2, NR2R2a, C (O) R2b, CO2R2b, CO2R2a, S (O) p R2, C (O) NR2R2a, SO2NR2R2a, NR2SO2R2, and 5-6 membered aromatic heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, 0, and S(0)p, and substituted with 0-2 R4b, provided that R1b forms other than an O-O, N-halo, N-S, or N-CN
bond;
R2, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, phenyl substituted with 0-1 R4b, benzyl substituted with 0-1 R4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R4b;
R2a, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, phenyl substituted with 0-1 R4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R4b;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-1 R4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)p;
R2b, at each occurrence, is selected from OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, phenyl substituted with 0-1 R4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R4b;
R2C, at each occurrence, is selected from OH, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, phenyl substituted with 0-1 R4b, and 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R4b;
R4, at each occurrence, is selected from OH, OR2, CH2OR2, (CH2)2OR2, F, Br, C1, I, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH (CH3)2, CH(CH3) CH2CH3, C(CH3)3, NR2R2a, CH2NR2R2a, (CH2)2NR2R2a, CF3, and CF2CF3;
R4a, at each occurrence, is selected from H, =O, CH2OR2, OR2, F, Br, C1, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, CH2NR2R2a, NR2R2a, C(O)R2c, NR2C(O)R2b, C(O)NR2R2a, SO2NR2R2a, and CF3;
R4b, at each occurrence, is selected from H, =O, OR3, CH2OR3, F, C1, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, -CN, NO2, NR3R3a, CH2NR3R3a, C(O)R3, C(O)OR3c, NR3C(O)R3a, C(O)NR3R3a, SO2NR3R3a, NR3SO2-C1-4 alkyl, NR3SO2-phenyl, S(O)p-C1-4 alkyl , S(O)p-phenyl , and CF3;
R4c, at each occurrence, is selected from H, CH3, CH2CH3, phenyl substituted with 0-1 R5, and benzyl substituted with 0-1 R5;
R5, at each occurrence, is selected from H, =O, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, OR3, CH2OR3, F, C1, -CN, NO2, NR3R3a, CH2NR3R3a, C(O)R3, C(O)OR3C, NR3C(O)R3a, C(O)NR3R3a, SO2NR3R3a, NR3SO2-C1-4 alkyl, NR3SO2-phenyl, S(O)p-C1-4 alkyl, S(O)p-phenyl, CF3, phenyl substituted with 0-2 R6, naphthyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6; and, R6, at each occurrence, is selected from H, OH, OR2, F, C1, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, -CN, NO2, NR2R2a, CH2NR2R2a, C(O)R2b, CH2C(O)R2b, NR2C(O)R2b, and SO2NR2R2a.
5. A compound according to Claim 4, wherein;
ring M is substituted with 0-1 R1a and is selected from the group:

ring P, including P1, P2, P3, and P4 is selected from group:

one of P4 and M4 is -A-B and the other -G;
G is selected from:

A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-C1-phenyl, 3-C1-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl;

B is attached to a different atom on A than M and is selected from the group:
R1a is selected from H, CH3, CH2CH3, CH2CH2CH3, CHEF, CH2Cl, Br, CH2Br, -CN, CH2CN, CF3, CH2CF3, OCH3, CH2OH, C(CH3)2OH, CH2OCH3, NH2, CH2NH2, NHCH3, CH2NHCH3, N(CH3)2, CH2N(CH3)2, CO2H, COCH3, CO2CH3, CH2CO2CH3, SCH3, CH2SCH3, S(O)CH3, CH2S(O)CH3, S(O)2CH3, CH2S(O)2CH3, C(O)NH2, CH2C(O)NH2, SO2NH2, CH2SO2NH2, NHSO2CH3, CH2NHSO2CH3, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridin-2-yl-N-oxide, pyridin-3-yl-N-oxide, pyridin-4-yl-N-oxide, imidazol-1-yl, CH2-imidazol-1-yl, 4-methyl-oxazol-2-yl, 4-N,N-dimethylaminomethyl-oxazol-2-yl, 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, CH2-1,2,3,4-tetrazol-1-yl, and CH2-1,2,3,4-tetrazol-5-yl, provided that R1a forms other than an N-halo, N-S, or N-CN bond;
R2, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, phenyl substituted with 0-1 R4b, benzyl substituted with 0-1 R4b, and 5 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R4b;

R2a, at each occurrence, is selected from H, CH3, and CH2CH3;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-1 R4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)p;
R2b, at each occurrence, is selected from OCH3, OCH2CH3, CH3, and CH2CH3;
R2c, at each occurrence, is selected from OH, OCH3, OCH2CH3, CH3, and CH2CH3;
R4a, at each occurrence, is selected from H, =O, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, and C(CH3)3;
R4b, at each occurrence, is selected from H, =O, OR3, CH2OR3, F, Cl, CH3, CH2CH3, NR3R3a, CH2NR3R3a, C(O)R3, C(O)OR3c, NR3C(O)R3a, C(O)NR3R3a, SO2NR3R3a, NR3SO2-phenyl, S(O)2CH3, S(O)2-phenyl, and CF3;
R5, at each occurrence, is selected from H, =O, CH3, CH2CH3, OR3, CH2OR3, F, Cl, NR3R3a, CH2NR3R3a, C(O)R3, C(O)OR3c, NR3C(O)R3a, C(O)NR3R3a, SO2NR3R3a, NR3SO2-C1-4 alkyl, NR3SO2-phenyl, S(O)2-CH3, S(O)2-phenyl, CF3, phenyl substituted with 0-2 R6, naphthyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6; and, R6, at each occurrence, is selected from H, OH, OR2, F, Cl, CH3, CH2CH3, NR2R2a, CH2NR2R2a, C(O)R2b, CH2C(O)R2b, NR2C(O)R2b, and SO2NR2R2a.
6. A compound according to Claim 5, wherein the compound is selected from:
P4 is -G;
M4 is -A-B;
G is selected from:
and, A-B is selected from:

7. A compound according to Claim 6, wherein the compound is selected from:
P4 is -G;
M4 is -A-B;
A-B is selected from:
8. A compound according to Claim 1, wherein the compound is selected from the group:
3-methoxy-1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-1,4,5,6-tetrahydro-7-H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-3-[(methylamino)methyl]-6-[4-(2-oxo-1-piperidinyl)phenyl]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(3-chloro-4-fluorophenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridine-7-one;
1-[3-(aminomethyl)-4-fluorophenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridine-7-one;
1-(3-amino-1,2-benzisoxazol-5-yl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridine-7-one;

1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-6-[4-(2-oxohexahydro-1H-azepin-1-yl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperazinyl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-6-[4-(2-oxo-1-imidazolidinyl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-6-[4-(2-oxotetrahydro-1(2H)-pyrimidinyl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
6-[4-(3-ethyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)phenyl]-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carbonitrile;
1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(1H-tetraazol-5-yl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl-4,5,6,7-tetrahydro-1H-pyrazole-[3,4-c]pyridine-3-carboxamide;

3-bromo-1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl) phenyl]1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(4-pyridinyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(4-pyridinyl-N-oxide)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(3-pyridinyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(3-pyridinyl-N-oxide)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-~
c]pyridin-7-one;
1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(2-pyridinyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]-7-one;
1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl) phenyl]1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-7-oxo-6-[5-(2-oxo-1-piperidinyl)2-pyridinyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;

1-(4-methoxyphenyl)-3-(methylsulfonyl)-6-[4-(2-oxo-1-~
piperidinyl)phenyl]1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

1-(4-methoxyphenyl)-6-(4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-(2-pyridinyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

1-[3-(aminomethyl)phenyl]-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

3-[7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl]benzamide;

1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;

1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1(2H)pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;

1-(3-chlorophenyl)-N,N-dimethyl-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;

1-(3-chloro-4-fluorophenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;

1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carbonitrile;

1-(3-amino-1H-indazol-5-yl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;

1-(3-amino-1,2-benzisoxazol-5-yl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;

1-(2,3-dihydro-1H-indol-6-yl)-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

1-(2,3-dihydro-1H-indol-6-yl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

1-(2,3-dihydro-1H-isoindol-5-yl)-6-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-3-trifluoromethyl-1,4,5,6-tetrahydropyrazolo[3,4-c]pyridin-7-one;

1,(4-methoxyphenyl)-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-3-(2-pyrrolidin-1-ylmethyl-phenyl)-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;

ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate;

1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid;

1-(4-methoxyphenyl)-N,N-dimethyl-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-~
c]pyridine-3-carboxamide;

N-({1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-yl}carbonyl)methanesulfonamide;
1-(4-hydroxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
1-(4-methoxyphenyl)-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-(1H-tetraazol-5-yl)-1,4,5,6,-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
3-{4-[dimethylamino)methyl]-1,3-oxazol-2-yl}-1-(4-methoxyphenyl)-6-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-1,4,5,6,-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
3-{4-[dimethylamino)methyl]-1,3-oxazol-2-yl}-1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-1,4,5,6,-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperazinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;
1-(4-methoxyphenyl)-3-(methylsulfonyl)-6-[4-(2-oxo-1-piperazinyl)phenyl]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxy-phenyl)-3-(4-methyl-oxazol-2-yl)-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxy-phenyl)-3-(4-methyl-oxazol-2-yl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;

3-acetyl-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;
3-(4,5-dihydro-1H-imidazol-2-yl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxy-phenyl)-3-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxy-phenyl)-3-(1-methyl-1H-imidazol-2-yl)-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;
1-(4-methoxy-phenyl)-3-methyl-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;
3-hydroxymethyl-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;
3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-1,4,5,6-tetrahydropyrazolo[3,4-c]pyridin-7-one;
3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;
2-dimethylamino-N-{1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-ylmethyl}-N-methylacetamide;

2-dimethylamino-N-{1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-2H-pyridin-1-y1)-phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-ylmethyl}acetamide;

N-{1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-ylmethyl}-2-pyridin-2-yl-acetamide;

N-{1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-ylmethyl}-2-(1-oxypyridin-2-yl)acetamide;

6-[4-(1,1-dioxo-116-isothiazolidin-2-yl)-phenyl]-1-(4-methoxy-phenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;

N-hydroxy-3-{7-oxo-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl}-benzamidine;

N-methoxy-3-{7-oxo-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl}-benzamidine;

1-(3-cyano-4-fluorophenyl-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;

1-(3-aminomethyl-4-fluoro-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;

2-{7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl}-benzenesulfonamide;

2-{7-oxo-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl}-benzenesulfonamide;

N-acetyl-2-{7-oxo-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3 trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4 c]pyridin-1-yl}-benzene.sulfonamide;

1-(3-chloro-phenyl)-3-methanesulfonyl-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;

1-(3-chloro-phenyl)-3-methanesulfonyl-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;

1-(3-chloro-phenyl)-3-(1-hydroxy-1-methyl-ethyl)-6-[4-(2 oxo-piperidin-1-yl)-phenyl]-1,4,5,6-tetrahydro pyrazolo[3,4-c]pyridin-7-one; and, 3-{7-oxo-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl}-benzamide;

or a pharmaceutically acceptable salt form thereof.
9. A compound according to Claim 1, wherein the compound is of Formula IIIa, IIIb, or IIIc:
or a stereoisomer.or pharmaceutically acceptable salt thereof, wherein;

ring M, including M1, M2, and, if present, M3, is phenyl or a 3-10 membered carbocyclic or 4-10 membered heterocyclic ring consisting of: carbon atoms and 1-4 heteroatoms selected from O, S(O)p, N; and NZ2;

ring M is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds;

one of P4 and M4 is -Z-A-B and the other -G1-G;

G is a group of Formula IIa or IIb:
ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of:
carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p;

ring D is substituted with 0-2 R and there are 0-3 ring double bonds;

E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and is substituted with 1-2 R;

alternatively, ring D is absent, and ring E is selected from phenyl, pyridyl, pyrimidyl, and thienyl, and ring E is substituted with 1-2 R;

alternatively, ring D is absent, ring E is selected from phenyl, pyridyl, and thienyl, and ring E is substituted with 1 R and substituted with a 5 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, wherein the 5 membered heterocycle is substituted with 0-1 carbonyl and 1-2 R and there are 0-3 ring double bonds;
R is selected from H, C1-4 alkyl, F, Cl, OH, OCH3, OCH2CH3, OCH(CH3)2, CN, C(=NH)NH2, C(=NH)NHOH, C(=NH)NHOCH3, NH2, NH(C1-3 alkyl), N(C1-3 alkyl), C(=NH)NH2, CH2NH2, CH2NH(C1-3 alkyl), CH2N(C1-3 alkyl), (CR8R9)t NR7R8, C(O)NR7R8, CH2C(O)NR7R8, S(O)p NR7R8, CH2S(O)p NR7R8, SO2R3, and OCF3;

alternatively, when 2 R groups are attached to adjacent atoms, they combine to form methylenedioxy or ethylenedioxy;
A is selected from:
C5-10 carbocycle substituted with 0-2 R4, and 5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4;
provided that A is other than a dihydro-benzopyran;

B is provided that Z and B are attached to different atoms on A and that the A-X-N moiety forms other than a N-N-N group;
provided that B is other than triazolone, quinolone, or isoquinolone, wherein the triazolone, quinolone, and isoquinolone groups are substituted or unsubstituted;

Q1 is selected from C=O and SO2;

ring Q is a 4-7 membered monocyclic or tricyclic ring consisting of, in addition to the N-Q1 group shown, carbon atoms and 0-2 heteroatoms selected from NR4c, O, S, S(O), and S(O)2, wherein:
0-2 double bonds are present within the ring and the ring is substituted with 0-2 R4a;

alternatively, ring Q is a 4-7 membered ring to which another ring is fused, wherein:
the 4-7 membered ring consists of, in addition to the shown amide group, carbon atoms and 0-2 heteroatoms selected from NR4c, O, S, S(O), and S(O)2, and 0-1 double bonds are present within the ring;
the fusion ring is phenyl or a 5-6 membered heteroaromatic consisting of carbon atoms and 1-2 heteroatoms selected from NR4c, O, and S;
ring Q, which includes the 4-7 membered ring and the fusion ring, is substituted with 0-3 R4a;

X is absent or is selected from -(CR2R2a)1-4-, -C(O)-, -C(O)CR2R2a-, -CR2R2aC(O), -S(O)2-, -S(O)2CR2R2a-, -CR2R2a S(O)2-, -NR2S(O)2-, -NR2CR2R2a-, and -OCR2R2a-;

Z is selected from a bond, CH2, CH2CH2, CH2O, OCH2, C(O), NH, CH2NH, NHCH2, CH2C(O), C(O)CH2, C(O)NH, NHC(O), NHC(O)NH, NHC(O)CH2C(O)NH, C(O)NHS(O)2, S(O)2, CH2S(O)2, S(O)2(CH2), SO2NH, and NHSO2, provided that Z
does not form a N-S, NCH2N, NCH2O, or NCH2S bond with either group to which it is attached;

Z2 is selected from H, C1-4 alkyl, phenyl, benzyl, C(O)R3b, S(O)R3f, and S(O)2R3f;

R1a is selected from H, -(CH2)r-R1b, -(CH (CH3))r-R1b -(C(CH3)2)r-R1b, NHCH2R1c, OCH2R1c, SCH2R1c, NH(CH2)2(CH2)t R1b, and O(CH2)2(CH2)t R1b, provided that R1a forms other than an N-halo, N-S, or N-CN bond;
alternatively, when two R1a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5-7 membered ring consisting of:
carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p, this ring being substituted with 0-2 R4b and 0-3 ring double bonds;
R1b is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, F, Cl, Br, I, -CN, -CHO, CF3, OR2, NR2R2a, C(O)R2b, CO2R2b, OC(O)R2, CO2R2a, S(O)p R2, NR2(CH2)r OR2, NR2C(O)R2b, NR2C(O)NHR2, NR2C(O)2R2a, OC(O)NR2R2a, C(O)NR2R2a, C(O)NR2(CH2)r OR2, SO2NR2R2a, NR2SO2R2, C5-6 carbocycle substituted with 0-2 R4b, and 5-6 membered heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b, provided that R1b forms other than an O-O, N-halo, N-S, or N-CN bond;
R1c is selected from H, CH(CH2OR2)2, C(O)R2c, C(O)NR2R2a, S(O)R2, S(O)2R2, and SO2NR2R2a;
R2, at each occurrence, is selected from H, CF3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)3, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl, C5-6 carbocycle substituted with 0-2 R4b, a C5-6 carbocyclic-CH2-group substituted with 0-2 R4b, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
R2a, at each occurrence, is selected from H, CF3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl, C5-6 carbocycle substituted with 0-2 R4b, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)p;
R2b, at each occurrence, is selected from CF3, C1-4 alkoxy, CH3, CH2CH3, CH2CH2CH3, CH(CH3), CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl, C5-6 carbocycle substituted with 0-2 R4b, and 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
R2c, at each occurrence, is selected from CF3, OH, C1-4 alkoxy, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3) CH2CH3, C(CH3)3, benzyl, C5-6 carbocycle substituted with 0-2 R4b, and 5-6 membered heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;

R3, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, and phenyl;

R3a, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, and phenyl;

alternatively, R3 and R3a, together with the nitrogen atom to which they are attached, combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring. consisting of: carbon atoms and the nitrogen atom to which R3 and R3a are attached;

R3c, at each occurrence, is selected from CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, and phenyl;

R3d, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2-phenyl, CH2CH2-phenyl, and C(=O)R3c;
R4, at each occurrence, is selected from H, =O, OR2, CH2OR2, (CH2)2OR2, F, Cl, Br, I, C1-4 alkyl, -CN, NO2, NR2R2a, CH2NR2R2a, (CH2)2NR2R2a, C(O)R2c, NR2C(O)R1b, C(O)NR2R2a, SO2NR2R2a, S(O)p R5a, CF3, CF2CF3, 5-6 membered carbocycle substituted with 0-1 R5, and a 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5;

R4a, at each occurrence, is selected from H, =O, CH2OR2, OR2, CH2F, F, CH2Br, Br, CH2Cl, Cl, C1-4 alkyl, CH2-CN, -CN, CH2NO2, NO2, CH2NR2R2a, NR2R2a, CH2-C(O)R2c,~
C(O)R2c, NR2C(O)R2b, (CH2)r C(O)NR2R2a, NR2C(O)NR2R2a, (CH2)r SO2NR2R2a, NR2SO2NR2R2a, NR2SO2-C1-4 alkyl, NR2SO2R5, (CH2)r S(O)p R5a, CH2CF3, CF3, CH2-5-6 membered carbocycle substituted with 0-1 R5, 5-6 membered carbocycle substituted with 0-1 R5, and a CH2-5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5, and 5-6 membered heterocycle consisting of:
carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5;

R4b, at each occurrence, is selected from H, =O, OR3, CH2OR3, F, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3 , CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, -CN, NO2, NR3R3a, CH2NR3R3a, C(O)R3, CH2-C(O)R3, C(O)OR3c, CH2C(O)OR3c, NR3C(O)R3a, CH2NR3C(O)R3a, C(O)NR3R3a, CH2C(O)NR3R3a, NR3C(O)NR3R3a, CH2NR3C(O)NR3R3a, C(=NR3)NR3R3a, CH2C(=NR3)NR3R3a, NR3C(=NR3)NR3R3a, CH2NR3C(=NR3)NR3R3a, SO2NR3R3a, CH2SO2NR3R3a, NR3SO2NR3R3a, CH2NR3SO2NR3R3a, NR3SO2-C1-4 alkyl, CH2NR3SO2-C1-4 alkyl, NR3SO2CF3, CH2NR3SO2CF3, NR3SO2-phenyl, CH2NR3SO2-phenyl, S(O)p CF3, CH2S(O)p CF3, S(O)p-C1-4 alkyl, CH2S(O)p-C1-4 alkyl, S(O)p-phenyl, CH2S(O)p-phenyl, CF3, and CH2-CF3;

R4c, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, CH2OR2, CH2F, CH2Br, CH2Cl, CH2CN, CH2NO2, CH2NR2R2a, C(O)R2c, CH2C(O)R2c, CH2NR2C(O)R2b, C(O)NR2R2a, CH2C(O)NR2R2a, CH2NR2C(O)NR2R2a, SO2NR2R2a, CH2SO2NR2R2a, CH2NR2SO2NR2R2a, CH2NR2SO2-C1-4 alkyl, C(O)NHSO2-C1-4 alkyl, CH2C(O)NHSO2-C1-4 alkyl, CH2NR2SO2R5, S(O)p R5a, CH2S(O)p R5a, CF3, CH2CF3, 5-6 membered carbocycle substituted with 0-1 R5, CH2 5-6 membered carbocycle substituted with 0-1 R5, 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5, and a CH2 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R5;

R5, at each occurrence, is selected from H, =O, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, OR3, CH2OR3, F, Cl, -CN, NO2, NR3R3a, CH2NR3R3a, C(O)R3, CH2C(O)R3, C(O)OR3c, CH2C(O)OR3c, NR3C(O)R3a, C(O)NR3R3a, NR3C(O)NR3R3a, CH(=NOR3d), C(=NR3)NR3R3a, NR3C(=NR3)NR3R3a, SO2NR3R3a, NR3SO2NR3R3a, NR3SO2-C1-4 alkyl, NR3SO2CF3, NR3SO2-phenyl, S(O)p CF3, S(O)p-C1-4 alkyl, S(O)p-phenyl, CF3, phenyl substituted with 0-2 R6, naphthyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6; and, R6, at each occurrence, is selected from H, OH, OR2, F, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, -CN, NO2, NR2R2a, CH2NR2R2a, C(O)R2b, CH2C(O)R2b, NR2C(O)R2b, NR2C(O)NR2R2a, C(=NH)NH2, NHC(=NH)NH2, SO2NR2R2a, NR2SO2NR2R2a, and NR2SO2C1-4 alkyl.
10. A compound according to Claim 9, wherein;
ring M, including M1, M2, and, if present, M3, is selected from phenyl, pyrrole, furan, thiophene, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, 1,2,3-triazole, 1,2,4-triazole, 1,3,4-triazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole, 1,2,3,4-tetrazole, 1,2,3,5-tetrazole, pyran, thiopyran, thiopyran=1,1-dioxide, pyridine, pyrimidine, pyridazine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,2,3,4-tetrazine, dihydro-pyrrole, dihydro-furan, dihydro-thiophene, dihydro-pyrazole, dihydro-imidazole, dihydro-isoxazole, dihydro-oxazole, dihydro-isothiazole, dihydro-thiazole, dihydro-1,2,3-triazole, dihydro-1,2,4-triazole, dihydro-1,3,4-triazole, dihydro-1,2,3-oxadiazole, dihydro-1,2,4-oxadiazole, dihydro-1,3,4-oxadiazole, dihydro-1,2,3-thiadiazole, dihydro-1,2,4-thiadiazole, dihydro-1,3,4-thiadiazole, dihydro-1,2,3,4-tetrazole, dihydro-1,2,3,5-tetrazole, dihydro-pyran, dihydro-thiopyran, dihydro-thiopyran=1,1-dioxide, dihydro-pyridine, dihydro-pyrimidine, dihydro-pyridazine, dihydro-pyrazine, dihydro-1,2,3-triazine, dihydro-1,2,4-triazine, dihydro-1,2,3,4-tetrazine, cyclopentene, cyclopentane, cyclohexene, cyclohexane, tetrahydro-pyrrole, tetrahydro-furan, tetrahydro-thiophene, tetrahydro-thiophene-1,1-dioxide, tetrahydro-pyrazole, tetrahydro-imidazole, tetrahydro-isoxazole, tetrahydro-oxazole, tetrahydro-isothiazole, tetrahydro-thiazole, tetrahydro-1,2,3-triazole, tetrahydro-1,2,4-triazole, tetrahydro-1,3,4-triazole, tetrahydro-1,2,3-oxadiazole, tetrahydro-1,2,4-oxadiazole, tetrahydro-1,3,4-oxadiazole, tetrahydro-1,2,3-thiadiazole, tetrahydro-1,2,4-thiadiazole, tetrahydro-1,3,4-thiadiazole, tetrahydro-1,2,3,4-tetrazole, tetrahydro-1,2,3,5-tetrazole, tetrahydro-pyran, tetrahydro-thiopyran, tetrahydro-thiopyran-1,1-dioxide, tetrahydro-pyridine, tetrahydro-pyrimidine, tetrahydro-pyridazine, tetrahydro-pyrazine, tetrahydro-1,2,3-triazine, tetrahydro-1,2,4-triazine, and tetrahydro-1,2,3,4-tetrazine;
ring M is substituted with 0-3 R1a and 0-1 carbonyl group;
G is selected from the group:

G1 is absent or is selected from (CR3R3a)1-3, (CR3R3a)u C(O) (CR3R3a)w, (CR3R3a)u O(CR3R3a)w, (CR3R3a)u NR3b(CR3R3a)w, (CR3R3a)u C(O)NR3b(CR3R3a)w, (CR3R3a)u NR3b C(O) (CR3R3a)w, (CR3R3a)u NR3b C(O) (CR3R3a)u C(O)NR3b(CR3R3a)w, (CR3R3a)u S(CR3R3a)w, (CR3R3a)u S(O) (CR3R3a)w, (CR3R3a)u S(O)2(CR3R3a)w, (CR3R3a)u S(O)NR3b(CR3R3a)w, (CR3R3a)u NR3b S(O)2(CR3R3a)w, (CR3R3a)u S(O)2NR3b(CR3R3a)w, and (CR3R3a)u C(O)NR3b S(O)2(CR3R3a)w, wherein u + w total 0, 1, or 2, provided that G1 does not form a N-S, NCH2N, NCH2O, or NCH2S bond with either group to which it is attached;

A is selected from one of the following carbocyclic and heterocyclic groups which are substituted with 0-2 R4;
phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thienyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolinyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;

B is provided that Z and B are attached to different atoms on A;
provided that B is other than triazolone, quinolone, or isoquinolone, wherein the triazolone, quinolone, and isoquinolone groups are substituted or unsubstituted;

Q1 is selected from C=0 and SO2;
ring Q is a 5-7 membered ring consisting of, in addition to the N-Q1 group shown, carbon atoms and 0-2 heteroatoms selected from NR4c, O, S, S(O), and S(O)2, wherein:
0-2 double bonds are present within the ring and the ring is substituted with 0-2 R4a;
alternatively, ring Q is a 5-7 membered ring to which another ring is fused, wherein:
the 5-7 membered ring consists of, in addition to the shown amide group, carbon atoms and 0-2 heteroatoms selected from NR4c, O, S, S(O), and S(O)2, and 0-1 double bonds are present within the ring;
the fusion ring is phenyl or a 5-6 membered heteroaromatic consisting of carbon atoms and 1-2 heteroatoms selected from NR4c, O, and S;
ring Q, which includes the 5-7 membered ring and the fusion ring, is substituted with 0-3 R4a;

R1a is selected from H, R1b, CH (CH3)R1b, C(CH3)2R1b, CH2R1b, and CH2CH2R1b, provided that R1a forms other than an N-halo, N-S, or N-CN bond;

alternatively, when two R1a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5-6 membered ring consisting of:

carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p, this ring being substituted with 0-2 R4b and 0-3 ring double bonds;

R1b is selected from H, CH3, CH2CH3, F, Cl, Br, -CN, -CHO, CF3 , OR2, NR2R2a, C(O)R2b, CO2R2b, OC(O)R2, CO2R2a, S(O)p R2, NR2(CH2)r OR2, NR2C(O)R2b, C(O)NR2R2a, SO2NR2R2a, NR2SO2R2, phenyl substituted with 0-2 R4b, and 5-6 membered aromatic heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b, provided that R1b forms other than an O-O, N-halo, N-S, or N-CN bond;
R2, at each occurrence, is selected from H, CF3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, phenyl substituted with 0-2 R4b, a benzyl substituted with 0-2 R4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b R2a, at each occurrence, is selected from H, CF3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, phenyl substituted with 0-2 R4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, 0, and S(O)p, and substituted with 0-2 R4b;

alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)p;
R2b, at each occurrence, is selected from CF3, C1-4 alkoxy, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, phenyl substituted with 0-2 R4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
R2c, at each occurrence, is selected from CF3, OH, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, phenyl substituted with 0-2 R4b, and 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b;
R4, at each occurrence, is selected from H, CH2OR2, (CH2)2OR2, OR2, F, Cl, Br, I, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, -CN, NO2, NR2R2a, CH2NR2R2a, (CH2)2NR2R2a, C(O)R2c, NR2C(O)R2b, C(O)NR2R2a, SO2NR2R2a, CF3, and CF2CF3;
R4a, at each occurrence, is selected from H, =O, CH2OR2, OR2, F, Br, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, -CN, NO2, CH2NR2R2a, NR2R2a, C(O)R2c, NR2C(O)R2b, C(O)NR2R2a, NR2C(O)NR2R2a, SO2NR2R2a, and -CF3;

R4b, at each occurrence, is selected from H, =O, OR3, CH2OR3, F, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, -CN, NO2, NR3R3a, CH2NR3R3a, C(O)R3, CH2-C(O)R3, C(O)OR3c, CH2-C(O)OR3c, NR3C(O)R3a, CH2NR3C(O)R3a, C(O)NR3R3a, CH2-C(O)NR3R3a, SO2NR3R3a, CH2SO2NR3R3a, NR3SO2-C1-4 alkyl, CH2NR3SO2-C1-4 alkyl, NR3SO2-phenyl, CH2NR3SO2-phenyl, S(O)p CF3, CH2S(O)p CF3, S(O)p-C1-4 alkyl, CH2S(O)p-C1-4 alkyl, S(O)p-phenyl, CH2S(O)p-phenyl, and CF3;

R4c, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, CH2OR2, CH2F, CH2Br, CH2Cl, CH2CN, CH2NO2, CH2NR2R2a, C(O)R2c, CH2C(O)R2c, CH2NR2C(O)R2b, C(O)NR2R2a, CH2C(O)NR2R2a, SO2NR2R2a, CH2SO2NR2R2a, S(O)p R5a, CH2S(O)p R5a, CF3, phenyl.

substituted with 0-1 R5, and benzyl substituted with 0-1 R5;
R5, at each occurrence, is selected from H, =O, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, OR3, CH2OR3, F, Cl, -CN, NO2, NR3R3a, CH2NR3R3a, C(O)R3, CH2C(O)R3, C(O)OR3c, CH2C(O)OR3c, NR3C(O)R3a, C(O)NR3R3a, SO2NR3R3a, NR3SO2-C1-4 alkyl, NR3SO2CF3, NR3SO2-phenyl, S(O)p CF3, S(O)p-C1-4 alkyl, S(O)p-phenyl, CF3, phenyl substituted with 0-2 R6, naphthyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6; and, R6, at each occurrence, is selected from H, OH, OR2, F, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, -CN, NO2, NR2R2a, CH2NR2R2a, C(O)R2b, CH2C(O)R2b, NR2C(O)R2b, SO2NR2R2a, and NR2SO2C1-4 alkyl.
11. A compound according to Claim 10, wherein the compound is selected from:

J is selected from O, S, NH, and NR1a G is selected from the group:

G1 is absent or is selected from CH2, CH2CH2, CH2O, OCH2, NH, CH2NH, NHCH2, CH2C(O), C(O)CH2, C(O)NH, NHC(O), NHC(O)NH, C(O)NHS(O)2, CH2S(O)2, S(O)2(CH2), SO2NH, and NHSO2, provided that G1 does not form a N-S, NCH2N, NCH2O, or NCH2S bond with either group to which it is attached;

A is selected from indolinyl, phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4;

B is ; provided that Z and B are attached to different atoms on A;
provided that B is other than triazolone, quinolone, or isoquinolone, wherein the triazolone, quinolone, and isoquinolone groups are substituted or unsubstituted;

Q1 is selected from C=O and SO2;
ring Q is a 6-7 membered ring consisting of, in addition to the N-Q1 group shown, carbon atoms and 0-1 heteroatoms selected from NR4c, O, S, S(O), and S(O)2, wherein:
0-2 double bonds are present within the ring and the ring is substituted with 0-2 R4a;
alternatively, ring Q is a 5-7 membered ring to which another ring is fused, wherein:
the 5-7 membered ring consists of, in addition to the shown amide group, carbon atoms and 0-1 heteroatoms selected from NR4C, O, S, S(O), and S(O)2, and 0-1 double bonds are present within the ring;
the fusion ring is phenyl;
ring Q, which includes the 5-7 membered ring and the fusion ring, is substituted with 0-2R4a;
R1a is selected from H, R1b, C(CH3)2R1b, and CH2R1b, provided that R1a forms other than an N-halo, N-S, or N-CN bond;
R1b is selected from CH3, CH2CH3, F, Cl, Br, -CN, CF3, OR2, NR2R2a, C(O)R2b, CO2R2b, CO2R2a, S(O)p R2, C(O)NR2R2a, SO2NR2R2a, NR2SO2R2, and 5-6 membered aromatic heterocycle consisting of carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-2 R4b, provided that R1b forms other than an O-O, N-halo, N-S, or N-CN
bond;
R2, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, phenyl substituted with 0-1 R4b, benzyl substituted with 0-1 R4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R4b;
R2a, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, phenyl substituted with 0-1 R4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R4b;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-1 R4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)p;
R2b, at each occurrence, is selected from OH, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, phenyl substituted with 0-1 R4b, and 5-6 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R4b;
R2c, at each occurrence, is selected from OH, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, benzyl, phenyl substituted with 0-1 R4b, and 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R4b;

R4, at each occurrence, is selected from OH, OR2, CH2OR2, (CH2)2OR2, F, Br, Cl, I, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, NR2R2a, CH2NR2R2a, (CH2)2NR2R2a, CF3, and CF2CF3;
R4a, at each occurrence, is selected from H, =O, CH2OR2, OR2, F, Br, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, CH2NR2R2a, NR2R2a, C(O)R2c, NR2C(O)R2b, C(O)NR2R2a, SO2NR2R2a, and CF3;
R4b, at each occurrence, is selected from H, =O, OR3, CH2OR3, F, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, -CN, NO2, NR3R3a, CH2NR3R3a, C(O)R3, C(O)OR3c, NR3C(O)R3a, C(O)NR3R3a, SO2NR3R3a, NR3SO2-C1-4 alkyl, NR3SO2-phenyl, S(O)p-C1-4 alkyl, S(O)p-phenyl, and CF3;
R42, at each occurrence, is selected from H, CH3, CH2CH3, phenyl substituted with 0-1 R5, and benzyl substituted with 0-1 R5;
R5, at each occurrence, is selected from H, =O, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, OR3, CH2OR3, F, Cl, -CN, NO2, NR3R3a, CH2NR3R3a, C(O)R3, C(O)OR3c, NR3C(O)R3a, C(O)NR3R3a, SO2NR3R3a, NR3SO2-C1-4 alkyl, NR3SO2-phenyl, S(O)p-C1-4 alkyl, S(O)p-phenyl, CF3, phenyl substituted with 0-2 R6, naphthyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6; and, R6, at each occurrence, is selected from H, OH, OR2, F, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, -CN, NO2, NR2R2a, CH2NR2R2a, C(O)R2b, CH2C(O)R2b, NR2C(O)R2b, and SO2NR2R2a.
12. A compound according to Claim 11, wherein the compound is selected from:
J is selected from O, S, NH, and NR1a;
P4 is -G1-G;
M4 is -Z-A-B;
G is selected from:

G1 is absent or is selected from CH2NH, NHCH2, CH2C(O), C(O)CH2, C(O)NH, NHC(O), NHC(O)NH, CH2S(O)2, S(O)2(CH2), SO2NH, and NHSO2, provided that G1 does not form a N-S, NCH2N, NCH2O, or NCH2S bond with either group to which it is attached;
A is selected from the group: indolinyl, phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl;

B is attached to a different atom on A than M and is selected from the group:
R1a is selected from H, CH3, CH2CH3, CH2CH2CH3, CH2F, CH2Cl, Br, CH2Br, -CN, CH2CN, CF3, CH2CF3, OCH3, CH2OH, C(CH3)2OH, CH2OCH3, NH2, CH2NH2, NHCH3, CH2NHCH3, N(CH3)2, CH2N(CH3)2, CO2H, COCH3, CO2CH3, CH2CO2CH3, SCH3, CH2SCH3, S(O)CH3, CH2S(O)CH3, S(O)2CH3, CH2S(O)2CH3, C(O)NH2, CH2C(O)NH2, SO2NH2, CH2SO2NH2, NHSO2CH3, CH2NHSO2CH3, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridin-2-yl-N-oxide, pyridin-3-yl-N-oxide, pyridin-4-yl-N-oxide, imidazol-1-yl, CH2-imidazol-1-yl, 4-methyl-oxazol-2-yl, 4-N,N-dimethylaminomethyl-oxazol-2-yl, 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, CH2-1,2,3,4-tetrazol-1-yl, and CH2-1,2,3,4-tetrazol-5-yl, provided that R1a forms other than an N-halo, N-S, or N-CN bond;
R2, at each occurrence, is selected from H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, phenyl substituted with 0-1 R4b, benzyl substituted with 0-1 R4b, and 5 membered aromatic heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, and substituted with 0-1 R4b;

R2a, at each occurrence, is selected from H, CH3, and CH2CH3;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-1 R4b and consisting of: 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)p;
R2b, at each occurrence, is selected from OCH3, OCH2CH3, CH3, and CH2CH3;
R2c, at each occurrence, is selected from OH, OCH3, OCH2CH3, CH3, and CH2CH3;
R4a, at each occurrence, is selected from H, =O, CH3, CH2CH3 , CH2CH2CH3 , CH(CH3)2 , CH2CH2CH2CH3, CH2CH2(CH3)2, CH(CH3)CH2CH3, and C(CH3)3;
R4b, at each occurrence, is selected from H, =O, OR3, CH2OR3, F, Cl, CH3, CH2CH3, NR3R3a, CH2NR3R3a, C(O)R3, C(O)OR3c, NR3C(O)R3a, C(O)NR3R3a, SO2NR3R3a, NR3SO2-phenyl, S(O)2CH3, S(O)2-phenyl, and CF3;
R5, at each occurrence, is selected from H, =O, CH3, CH2CH3, OR3, CH2OR3, F, Cl, NR3R3a, CH2NR3R3a, C(O)R3, C(O)OR3C, NR3C(O)R3a, C(O)NR3R3a, SO2NR3R3a, NR3SO2-C1-4 alkyl, NR3SO2-phenyl, S(O)2-CH3, S(O)2-phenyl, CF3, phenyl substituted with 0-2 R6, naphthyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6; and, R6, at each occurrence, is selected from H, OH, OR2, F, Cl, CH3, CH2CH3, NR2R2a, CH2NR2R2a, C(O)R2b, CH2C(O)R2b, NR2C(O)R2b, and SO2NR2R2a.
13. A compound according to Claim 12, wherein the compound is selected from:

G is selected from:

and, A-B is selected from:

14. A compound according to Claim 13, wherein the compound is selected from:

P4 is -G; and A-B is selected from:

15. A compound according to Claim 1, wherein the compound is selected from the group:

1-(3-amino-1,2-benzisoxazol-5-yl)-5-{[5-(2-oxo-1-piperidinyl)-2,3-dihydro-1H-indol-1-yl]carbonyl}-1H-pyrazole-3-carboxamide;
1-(3-amino-1,2-benzisoxazol-5-yl)-5-{[6-(2-oxo-1-piperidinyl)-2,3-dihydro-1H-indol-1-yl]carbonyl}-1H-pyrazole-3-carboxamide;
1-(3-amino-1,2-benzisoxazol-5-yl)-5-{[5-(2-oxohexahydro-1H-azepin-1-yl)-2,3-dihydro-1H-indol-1-yl]carbonyl}-1H-pyrazole-3-carboxamide;
1-(3-amino-1,2-benzisoxazol-5-yl)-5-{[6-(2-oxohexahydro-1H-azepin-1-yl)-2,3-dihydro-1H-indol-1-yl]carbonyl}-1H-pyrazole-3-carboxamide;
2-[(4-chlorobenzoyl)amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]benzamide;

2-[(4-chlorobenzoyl)amino]-N-[4-(2-oxo-1(2H) -pyridinyl)phenyl]benzamide;
2-[(4-chlorobenzoyl)amino]-N-[4-(2-oxotetrahydro-1(2H)-pyrimidinyl)phenyl]benzamide;
5-chloro-N-[2-({[4-(2-oxo-1-piperidinyl)phenyl]amino}carbonyl)phenyl]-2-pyridinecarboxamide;
5-chloro-N-[2-({[4-(2-oxo-1(2H) -pyridinyl)phenyl]amino}carbonyl)phenyl]-2-pyridinecarboxamide;
5-chloro-N-[2-({[4-(2-oxotetrahydro-1(2H) -pyrimidinyl)phenyl]amino}carbonyl)phenyl]-2-pyridinecarboxamide;
4-chloro-2-[(4-chlorobenzoyl)amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]benzamide;
4-chloro-2-[(4-chlorobenzoyl)amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]benzamide;
4-chloro-2-[(4-chlorobenzoyl)amino]-N-[4-(2-oxotetrahydro-1(2H)-pyrimidinyl)phenyl]benzamide;
2-[(4-chlorobenzoyl)amino]-4-[(methylsulfonyl)amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]benzamide;
2-[(4-chlorobenzoyl)amino]-4-[(methylsulfonyl)amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]benzamide;
2-[(4-chlorobenzoyl)amino]-4-[(methylsulfonyl)amino]-N-[4-(2-oxotetrahydro-1(2H)-pyrimidinyl)phenyl]benzamide;

5-chloro-N-[5-[(methylsulfonyl)amino]-2-({[4-(2-oxo-1-piperidinyl)phenyl]amino}carbonyl)phenyl]-2-pyridinecarboxamide;
2-[(4-chlorobenzoyl)amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]nicotinamide;
3-[(4-chlorobenzoyl)amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]isonicotinamide;
4-[(4-chlorobenzoyl)amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]nicotinamide;
5-chloro-N-[3-({[4-(2-oxo-1-piperidinyl)phenyl]amino}carbonyl)-4-pyridinyl]-2-pyridinecarboxamide;
5-chloro-N-[3-({[4-(2-oxo-1(2H)-pyridinyl)phenyl]amino}carbonyl)-4-pyridinyl]-2-pyridinecarboxamide;
5-chloro-N-[5-chloro-3-methoxy-2-({[4-(2-oxo-1(2H)-pyridinyl)phenyl]amino}carbonyl)phenyl]-2-pyridinecarboxamide;
5-chloro-N-[5-chloro-3-methoxy-2-({[4-(2-oxo-1-piperidinyl)phenyl]amino}carbonyl)phenyl]-2-pyridinecarboxamide;
methyl 2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]-3-oxopropanoate;
1-(3-fluoro-4-{2-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole-5-yl]-2-oxoethyl}phenyl)-2(1H)-pyridinone;

1-(4-{2-[1-(3-amino-1,2-benzisoxazol-5-yl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]-2-oxoethyl}-3-fluorophenyl)-2(1H)-pyridinone;
5-{[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]acetyl}-1-(4-methoxyphenyl)-1H-pyrazole-3-carboxamide;
1-(3-amino-1,2-benzisoxazol-5-yl)-5-{[5-(2-oxo-1(2H)-pyridinyl)-2,3-dihydro-1H-indol-1-yl]carbonyl}-1H-pyrazole-3-carboxamide;
5-chloro-N-(5-chloropyridin-2-yl)-2-({4-[(2-oxo-piperidine)-1-yl]benzoyl}amino)benzamide;
5-chloro-N-(5-chloropyridin-2-yl)-2-({4-[(2-oxo-pyridin)-1-yl]benzoyl}amino)benzamide;
N-(5-chloropyridin-2-yl)-2-({4-[(2-oxo-piperidine)-1-yl]benzoyl}amino)-5-methoxybenzamide;
N-(5-chloropyridin-2-yl)-2-({4-[(2-oxo-pyridin)-1-yl]benzoyl}amino)-5-methoxybenzamide;
N-(5-chloropyridin-2-yl)-2-({4-[(2-oxo-piperidin)-1-yl]benzoyl}amino)-5-methylbenzamide;
N-(5-chloropyridin-2-yl)-2-({4-[(2-oxo-pyridin)-1-yl]benzoyl}amino)-5-methylbenzamide;
2-(5-chloro-pyridin-2-yl)-7-methoxy-3-[4-(2-oxo-piperidin-1-yl)-phenyl]-2H-isoquinolin-1-one;
2-(5-chloro-pyridin-2-yl)-7-methoxy-3-[4-(2-oxo-pyridin-1-yl)-phenyl]-2H-isoquinolin-1-one;

5-chloro-N-(5-chloropyridin-2-yl)-3-methoxy-2-[4-(2-oxopiperidin-1-yl)-benzoylamino]benzamide;
5-chloro-N-(5-chloropyridin-2-yl)-3-methoxy-2-[4-(2-oxo-2H-pyridin-1-yl)-benzoylamino]benzamide;
3-chloro-N-(1,2-cis-2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclohexyl)-1H-indole-6-carboxamide ;
5-chloro-N-(1,2-cis-2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclohexyl)-1H-indole-2-carboxamide ;
5-chloro-N-(1,2-cis-2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide ;
5-chloro-N-(1,2-cis-2-{[4-(2-oxopyrazin-1(2H)-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide;
5-chloro-N-(1,2-cis-2-{[4-(2-oxopyrazin-1(2H)-yl)benzoyl]amino}cyclohexyl)-1H-indole-2-carboxamide;
3-chloro-N-(1,2-cis-2-{[4-(2-oxopyrazin-1(2H)-yl)benzoyl]amino}cyclohexyl)-1H-indole-6-carboxamide;
5-chloro-N-(1,2-cis-2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide;
5-chloro-N-(1,2-cis-2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)-1H-indole-2-carboxamide;
3-chloro-N-(1,2-cis-2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)-1H-indole-6-carboxamide;
3-chloro-N-(2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclohexyl)-1H-indole-6-carboxamide;

3-chloro-N-(2-{[4-(2-oxopyrazin-1(2H)-yl)benzoyl]amino}cyclohexyl)-1H-indole-6-carboxamide;
3-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)-1H-indole-6-carboxamide;
3-chloro-N-(2-{[4-(3-oxomorpholin-4-yl)benzoyl]amino}cyclohexyl)-1H-indole-6-carboxamide;
3-chloro-N-(2-{[4-(2-oxopiperazin-1-yl)benzoyl]amino}cyclohexyl)-1H-indole-6-carboxamide;
3-chloro-N-(2-{[4-(2-oxo-1,3-oxazinan-3-yl)benzoyl]amino}cyclohexyl)-1H-indole-6-carboxamide;
3-chloro-N-(3-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}tetrahydro-2H-pyran-4-yl)-1H-indole-6-carboxamide ;
3-chloro-N-(4-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}tetrahydro-2H-pyran-3-yl)-1H-indole-6-carboxamide;
3-chloro-N-(4-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}piperidin-3-yl)-1H-indole-6-carboxamide;
3-chloro-N-(3-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}piperidin-4-yl)-1H-indole-6-carboxamide ;
3-chloro-N-(4-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}pyrrolidin-3-yl)-1H-indole-6-carboxamide ;

3-chloro-N-(4-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}tetrahydrofuran-3-yl)-1H-indole-6-carboxamide;
3-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclopentyl)-1H-indole-6-carboxamide 3-chloro-N-(1,1-dioxido-4-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}tetrahydro-3-thienyl)-1H-indole-6-carboxamide;
3-chloro-N- (1, 1-dioxido-4-{ [4- (2-oxopyridin-1 (2H) -yl)benzoyl]amino}tetrahydro-2H-thiopyran-3-yl)-1H-indole-6-carboxamide;
3-chloro-N-(1,1-dioxido-3-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}tetrahydro-2H-thiopyran-4-yl)-1H-indole-6-carboxamide;
N-(2-{[(3-chloro-1H-indol-6-yl)sulfonyl]methyl}cyclohexyl)-4-(2-oxopiperidin-1-yl)benzamide;
N-(2-{[(6-chloro-2-naphthyl)sulfonyl]methyl}cyclohexyl)-4-(2-oxopiperidin-1-yl)benzamide;
5-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide 5-chloro-N-(2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide ;
5-chloro-N-(2-{[4-(2-oxopyrazin-1(2H)-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide ;

5-chloro-N-(2-{[4-(3-oxomorpholin-4-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide;
5-chloro-N-(2-{[4-(2-oxopiperazin-1-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide;
5-chloro-N-(2-{[4-(2-oxo-1,3-oxazinan-3-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide;
5-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclopentyl)thiophene-2-carboxamide ;
5-chloro-N-(2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclopentyl)thiophene-2-carboxamide;
5-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)-1H-indole-2-carboxamide 5-chloro-N-(2-{[4-(2-oxopyridin-1 (2H)-yl)benzoyl]amino}cyclohexyl)-1H-indole-2-carboxamide;
5-chloro-N-(2-{[4-(2-oxopyrazin-1 (2H)-yl)benzoyl]amino}cyclohexyl)-1H-indole-2-carboxamide;
5-chloro-N-(2-{[4-(3-oxomorpholin-4-yl)benzoyl]amino}cyclohexyl)-1H-indole-2-carboxamide;
5-chloro-N-(2-{[4-(2-oxopiperazin-1-yl)benzoyl]amino}cyclohexyl)-1H-indole-2-carboxamide;
5-chloro-N-(2-{[4-(2-oxo-1,3-oxazinan-3-yl)benzoyl]amino}cyclohexyl)-1H-indole-2-carboxamide;
5-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclopentyl)-1H-indole-2-carboxamide;

5-chloro-N-(2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclopentyl)-1H-indole-2-carboxamide;
6-chloro-N-(2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclohexyl)-2-naphthamide;
6-chloro-N-(2-{[4-(2-oxopiperazin-1-yl)benzoyl]amino}cyclohexyl)-2-naphthamide;
6-chloro-N-(2-{[4-(2-oxopyridin-1 (2H)-yl)benzoyl]amino}cyclohexyl)-2-naphthamide;
6-chloro-N-(2-{[4-(2-oxo-1,3-oxazinan-3-yl)benzoyl]amino}cyclohexyl)-2-naphthamide;
6-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)-2-naphthamide;
6-chloro-N-(2-{[4-(3-oxomorpholin-4-yl)benzoyl]amino}cyclohexyl)-2-naphthamide;
6-chloro-N-(2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclopentyl)-2-naphthamide;
6-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclopentyl)-2-naphthamide;
2-chloro-N- (2-{ [4- (2-oxopyridin-1 (2H) -yl)benzoyl]amino}cyclohexyl)quinoline-6-carboxamide;
2-chloro-N-(2-{[4-(2-oxopiperazin-1-yl)benzoyl]amino}cyclohexyl)quinoline-6-carboxamide;
2-chloro-N-(2-{[4-(2-oxo-1,3-oxazinan-3-yl)benzoyl]amino}cyclohexyl)quinoline-6-carboxamide;

2-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)quinoline-6-carboxamide;
2-chloro-N-(2-{[4-(3-oxomorpholin-4-yl)benzoyl]amino}cyclohexyl)quinoline-6-carboxamide;
2-chloro-N-(2-{[4-(2-oxopyridin-1(2H) -yl)benzoyl]amino}pentyl)quinoline-6-carboxamide;
2-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclopentyl)quinoline-6-carboxamide;
6-chloro-N-(2-{[4-(2-oxopyridin-1(2H) -yl)benzoyl],amino}cyclohextyl)-1-benzothiophene-2-carboxamide;
6-chloro-N-(2-{[4-(2-oxopiperazin-1-yl)benzoyl]amino}cyclohexyl)-1-benzothiophene-2-carboxamide;
6-chloro-N-(2-{[4-(2-oxo-1,3-oxazinan-3-yl)benzoyl]amino}cyclohexyl)-1-benzothiophene-2-carboxamide ;
6-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)-1-benzothiophene-2-carboxamide;
6-chloro-N-(2-{[4-(3-oxomorpholin-4-yl)benzoyl]amino}cyclohexyl)-1-benzothiophene-2-carboxamide;
6-chloro-N-(2-{[4-(2-oxopyridin-1(2H) -yl)benzoyl]amino}cyclopentyl)-1-benzothiophene-2-carboxamide;

6-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclopentyl)-1-benzothiophene-2-carboxamide;
6-chloro-N-(2-{[4-(2-oxopyridin-1(2H) -yl)benzoyl]amino}cyclohexyl)thieno[2,3-b]pyridine-2-carboxamide;
6-chloro-N-(2-{[4-(2-oxopiperazin-1-yl)benzoyl]amino}cyclohexyl)thieno[2,3-b]pyridine-2-carboxamide;
6-chloro-N-(2-{[4-(2-oxo-1,3-oxazinan-3-yl)benzoyl]amino}cyclohexyl)thieno[2,3-b]pyridine-2-carboxamide;
6-chloro-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)thieno[2,3-b]pyridine-2-carboxamide;
6-chloro-N-(2-{[4-(3-oxomorpholin-4-yl)benzoyl]amino}cyclohexyl)thieno[2,3-b]pyridine-2-carboxamide;
6-chloro-N-(2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclopentyl)thieno[2,3-b]pyridine-2-carboxamide;
6-chloro-N-(2-{[4-(2-oxopiperidin-1(2H)-yl)benzoyl]amino}cyclopentyl)thieno[2,3-b]pyridine-2-carboxamide;
5-methoxy-N-(2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclohextyl)thiophene-2-carboxamide;

5-methoxy-N-(2-{[4-(2-oxopiperazin-1-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide;
5-methoxy-N-(2-{[4-(2-oxo-1,3-oxazinan-3-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide;
5-methoxy-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide;
5-methoxy-N-(2-{[4-(3-oxomorpholin-4-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide;
5-methoxy-N-(2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclopentyl)thiophene-2-carboxamide;
5-methoxy-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)thiophene-2-carboxamide;
4-methoxy-N-(2-{[4-(2-oxopyridin-1(2H) -yl)benzoyl]amino}cyclohexyl)benzamide;
4-methoxy-N-(2-{[4-(2-oxopiperazin-1-yl)benzoyl]amino}cyclohexyl)benzamide;
4-methoxy-N-(2-{[4-(2-oxo-1,3-oxazinan-3-yl)benzoyl]amino}cyclohexyl)benzamide;
4-methoxy-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclohexyl)benzamide;
4-methoxy-N-(2-{[4-(3-oxomorpholin-4-yl)benzoyl]amino}cyclohexyl)benzamide;
4-methoxy-N-(2-{[4-(2-oxopyridin-1(2H)-yl)benzoyl]amino}cyclopentyl)benzamide;

4-methoxy-N-(2-{[4-(2-oxopiperidin-1-yl)benzoyl]amino}cyclopentyl)benzamide;
or a pharmaceutically acceptable salt form thereof.
16. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of any one of claims 1-15 or a pharmaceutically acceptable salt form thereof.
17. Use of a compound of any one of claims 1-15 or a pharmaceutically acceptable salt form thereof in the manufacture of a medicament for treating a thromboembolic disorder.
18. Use of a compound according to Claim 17, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.
19. Use of a compound according to Claim 17, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stems, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.
20. A compound of any one of claims 1-15 or a pharmaceutically acceptable salt form thereof for use in therapy.
CA2461202A 2001-09-21 2002-09-17 Lactam-containing compounds and derivatives thereof as factor xa inhibitors Expired - Lifetime CA2461202C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2726702A CA2726702A1 (en) 2001-09-21 2002-09-17 Lactam-containing compounds and derivatives thereof as factor xa inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32416501P 2001-09-21 2001-09-21
US60/324,165 2001-09-21
PCT/US2002/029491 WO2003026652A1 (en) 2001-09-21 2002-09-17 Lactam-containing compounds and derivatives thereof as factor xa inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2726702A Division CA2726702A1 (en) 2001-09-21 2002-09-17 Lactam-containing compounds and derivatives thereof as factor xa inhibitors

Publications (2)

Publication Number Publication Date
CA2461202A1 true CA2461202A1 (en) 2003-04-03
CA2461202C CA2461202C (en) 2011-07-12

Family

ID=23262376

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2461202A Expired - Lifetime CA2461202C (en) 2001-09-21 2002-09-17 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2726702A Abandoned CA2726702A1 (en) 2001-09-21 2002-09-17 Lactam-containing compounds and derivatives thereof as factor xa inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2726702A Abandoned CA2726702A1 (en) 2001-09-21 2002-09-17 Lactam-containing compounds and derivatives thereof as factor xa inhibitors

Country Status (39)

Country Link
US (11) US7338963B2 (en)
EP (2) EP1427415B1 (en)
JP (2) JP4249621B2 (en)
KR (2) KR100908176B1 (en)
CN (5) CN102617567A (en)
AR (2) AR037092A1 (en)
AT (2) ATE439360T1 (en)
AU (2) AU2002341693B2 (en)
BE (1) BE2011C034I2 (en)
BR (1) BRPI0212726B8 (en)
CA (2) CA2461202C (en)
CH (1) CH1427415H1 (en)
CL (1) CL2008002717A1 (en)
CO (1) CO5560567A2 (en)
CY (2) CY1110509T1 (en)
DE (2) DE60233335D1 (en)
DK (1) DK1427415T3 (en)
ES (1) ES2329881T3 (en)
FR (1) FR11C0042I2 (en)
GE (1) GEP20074098B (en)
HR (2) HRP20080382A2 (en)
HU (2) HU228195B1 (en)
IL (3) IL160693A0 (en)
IS (2) IS3006B (en)
LT (1) LTC1427415I2 (en)
LU (1) LU91888I2 (en)
ME (2) ME00384B (en)
MX (1) MXPA04002526A (en)
MY (1) MY137830A (en)
NO (4) NO328558B1 (en)
NZ (1) NZ531616A (en)
PL (2) PL204263B1 (en)
PT (1) PT1427415E (en)
RS (2) RS51444B (en)
RU (2) RU2345993C2 (en)
SI (1) SI1427415T1 (en)
UA (1) UA78232C2 (en)
WO (1) WO2003026652A1 (en)
ZA (1) ZA200402184B (en)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
PL368402A1 (en) * 2001-08-09 2005-03-21 Daiichi Pharmaceutical Co, Ltd. Diamine derivatives
SE0102764D0 (en) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
CA2461202C (en) 2001-09-21 2011-07-12 Donald Pinto Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TW200738672A (en) * 2001-12-10 2007-10-16 Bristol Myers Squibb Co Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
US20060229335A1 (en) * 2002-12-24 2006-10-12 Bradley Teegarden Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
JP4630267B2 (en) * 2002-12-25 2011-02-09 第一三共株式会社 Diamine derivatives
JP4109288B2 (en) * 2002-12-25 2008-07-02 第一三共株式会社 Diamine derivatives
US7205318B2 (en) * 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
PT1558582E (en) 2003-07-22 2006-05-31 Arena Pharm Inc DIARIL- AND ARIL-HETEROARIL-UREA DERIVATIVES AS SEROTONIN 5-HT2A RECEPTOR MODULES USEFUL FOR PROPHYLAXIS AND TREATMENT OF RELEVANT DISORDERS
KR20060041309A (en) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200512181A (en) * 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
US20050119266A1 (en) * 2003-10-01 2005-06-02 Yan Shi Pyrrolidine and piperidine derivatives as factor Xa inhibitors
EP1670739A4 (en) * 2003-10-08 2007-08-08 Bristol Myers Squibb Co Cyclic diamines and derivatives as factor xa inhibitors
MXPA06009301A (en) 2004-02-24 2007-01-26 Sumitomo Chem Takeda Agro Co INSECTICIDE COMPOSITIONS.
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102127057A (en) 2004-03-15 2011-07-20 武田药品工业株式会社 Dipeptidyl peptidase inhibitors
CA2559038C (en) * 2004-03-23 2013-09-10 Arena Pharmaceuticals, Inc. Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
TWI396686B (en) 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic guanamine derivatives, as well as their products and usage
ITMI20041032A1 (en) * 2004-05-24 2004-08-24 Neuroscienze S C A R L PHARMACEUTICAL COMPOSITES
JP2008501714A (en) 2004-06-04 2008-01-24 武田薬品工業株式会社 Dipeptidyl peptidase inhibitor
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7388096B2 (en) 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
CN101068812B (en) * 2004-09-28 2010-09-29 布里斯托尔-迈尔斯斯奎布公司 Efficient synthesis of 4, 5-dihydro-pyrazolo [3,4-c ] pyridin-2-ones
US7396932B2 (en) * 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7304157B2 (en) 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
SA05260357B1 (en) * 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك 3-phenyle-pyrazole derivatives as modulators of the 5-ht 2a serotonin receptor useful for the treatment of disorders related thereto
DE102004059219A1 (en) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Pyrazine dicarboxylic acid amides and their use
JP2008524228A (en) * 2004-12-15 2008-07-10 ブリストル−マイヤーズ スクイブ カンパニー Crystal form of factor XA inhibitor
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
EP1954696B1 (en) 2005-01-19 2011-02-23 Bristol-Myers Squibb Company 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
JP2006298909A (en) * 2005-03-25 2006-11-02 Tanabe Seiyaku Co Ltd Pharmaceutical composition
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
EP1899299B1 (en) 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
AR056867A1 (en) 2005-06-27 2007-10-31 Bristol Myers Squibb Co HETEROCICLIC ANTAGONISTS N- LINKED TO THE RECEIVER OF P2Y1 USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS. PHARMACEUTICAL COMPOSITIONS.
DE602006020871D1 (en) 2005-06-27 2011-05-05 Bristol Myers Squibb Co LINEAR UREA MIMETIC ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSELEIDES
CA2614746C (en) 2005-07-09 2011-05-10 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
GEP20135838B (en) 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
CN101360723A (en) 2005-09-16 2009-02-04 武田药品工业株式会社 Process for preparing pyrimidinedione derivatives
TW200734304A (en) 2005-11-08 2007-09-16 Astellas Pharma Inc Benzene derivative or salt thereof
US20090227598A1 (en) * 2006-01-24 2009-09-10 Buser-Doepner Carolyn A Ret Tyrosine Kinase Inhibition
WO2007087246A2 (en) * 2006-01-24 2007-08-02 Merck & Co., Inc. Jak2 tyrosine kinase inhibition
JP5286254B2 (en) 2006-05-18 2013-09-11 アリーナ ファーマシューティカルズ， インコーポレイテッド Crystalline forms of phenylpyrazole useful as modulators of 5-HT2A serotonin receptor activity and methods of preparation
CA2646076C (en) 2006-05-18 2015-06-30 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
ES2536762T3 (en) 2006-05-18 2015-05-28 Arena Pharmaceuticals, Inc. Primary amines and their derivatives as 5-HT2A serotonin receptor modulators useful for the treatment of disorders related to this
DE102006025314A1 (en) 2006-05-31 2007-12-06 Bayer Healthcare Ag Aryl-substituted heterocycles and their use
DE102006025315A1 (en) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Tetrahydro-pyrrolopyridine, tetrahydro-pyrazolopyridine, tetrahydro-imidazopyridine and tetrahydro-triazolopyridine derivatives and their use
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TWI415845B (en) * 2006-10-03 2013-11-21 Arena Pharm Inc Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE102006051625A1 (en) 2006-11-02 2008-05-08 Bayer Materialscience Ag Combination therapy of substituted oxazolidinones
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CN101605779B (en) 2006-12-15 2013-11-20 百时美施贵宝公司 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (en) 2006-12-20 2008-12-18 Bristol Myers Squibb Co MACROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
KR20100015886A (en) 2007-04-23 2010-02-12 사노피-아벤티스 Quinoline-carboxamide derivatives as p2y12 antagonists
DE102007028407A1 (en) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007028406A1 (en) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007028319A1 (en) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007032344A1 (en) 2007-07-11 2009-01-15 Bayer Healthcare Ag Prodrug derivatives of 1- (4-methoxyphenyl) -7-oxo-6- [4- (2-oxopiperidin-1-yl) phenyl] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4 -c] pyridine-3-carboxamide
WO2009023253A2 (en) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2009134203A1 (en) * 2008-04-30 2009-11-05 Fredrik Almqvist New peptidomimetic compounds
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CN104739829B (en) 2008-10-28 2018-11-06 艾尼纳制药公司 For treating 5-HT2AThe 5-HT of 5-hydroxytryptamine receptor associated disorders2A5-hydroxytryptamine receptor regulating composition
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
ES2674745T3 (en) 2010-02-11 2018-07-03 Bristol-Myers Squibb Company Macrocycles as inhibitors of factor XIa
IN2012DN06587A (en) * 2010-02-25 2015-10-23 Bristol Myers Squibb Co
WO2012098089A1 (en) 2011-01-19 2012-07-26 Bayer Pharma Aktiengesellschaft Binding proteins to inhibitors of coagulation factors
ITMI20111047A1 (en) * 2011-06-10 2012-12-11 Dipharma Francis Srl CRYSTAL FORM OF APIXABAN
EP2718262B1 (en) 2011-06-10 2016-08-03 Dipharma Francis S.r.l. Apixaban preparation process
EP2554159A1 (en) 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
TW201311689A (en) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 Novel macrocyclic compounds as factor XIA inhibitors
TW201319068A (en) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 Cyclic P1 linkers as factor XIa inhibitors
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2579832T3 (en) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
KR101937514B1 (en) 2011-10-14 2019-01-10 브리스톨-마이어스 스큅 컴퍼니 Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CN202271910U (en) * 2011-10-31 2012-06-13 潘磊 Multifunctional rearview mirror of automobile
CN103242310A (en) * 2012-02-10 2013-08-14 苏州迈泰生物技术有限公司 Pyrazolo pyridone compound and its application in preparation of anticoagulant
CA2865511A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical Heterocyclic compound
US20150272891A1 (en) 2012-05-24 2015-10-01 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
MX361759B (en) 2012-08-03 2018-12-17 Bristol Myers Squibb Co Dihydropyridone p1 as factor xia inhibitors.
KR20150038369A (en) 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 Dihydropyridone p1 as factor xia inhibitors
WO2014044107A1 (en) * 2012-09-18 2014-03-27 上海恒瑞医药有限公司 Pyrazol[3,4-c] pyridine derivative, preparation method and use in medicine thereof
MY179191A (en) * 2012-09-26 2020-10-30 Pfizer Apixaban liquid formulations
WO2014056434A1 (en) * 2012-10-10 2014-04-17 Sunshine Lake Pharma Co., Ltd. Crystalline form and amorphous form of apixaban and preparation thereof
CA2890002A1 (en) * 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
CZ304846B6 (en) 2012-11-13 2014-12-03 Zentiva, K.S. Process for preparing APIXABAN
EP2752414A1 (en) 2013-01-04 2014-07-09 Sandoz AG Crystalline form of apixaban
WO2014115020A1 (en) * 2013-01-24 2014-07-31 Universita' Degli Studi Di Bari Heterocycles and their radiolabeled analogs useful as cox-1 selective inhibitors
CN103539795A (en) * 2013-03-18 2014-01-29 齐鲁制药有限公司 Apixaban polymorph and preparation method thereof
ES2712699T3 (en) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahydroisoquinolines containing substituted azoles as inhibitors of factor XIa
CN104109165A (en) * 2013-04-19 2014-10-22 四川海思科制药有限公司 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-one derivatives, and preparation method and application thereof
CZ2013305A3 (en) 2013-04-23 2014-11-05 Zentiva, K.S. Novel crystalline forms of APIXABAN and process of their preparation
US20160113912A1 (en) 2013-06-18 2016-04-28 Cadila Healthcare Limited An improved process for the preparation of apixaban and intermediates thereof
CN104370902A (en) * 2013-08-12 2015-02-25 药源药物化学（上海）有限公司 Apixaban novel crystal form and preparation method thereof
US9611223B2 (en) 2013-09-11 2017-04-04 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CN104650072B (en) 2013-11-18 2016-03-16 成都苑东生物制药股份有限公司 A kind of pyridine derivatives
SG11201604611SA (en) 2013-12-18 2016-07-28 Glaxosmithkline Ip Dev Ltd Nrf2 regulators
NO2760821T3 (en) 2014-01-31 2018-03-10
CN116987080A (en) 2014-01-31 2023-11-03 百时美施贵宝公司 Macrocyclic compounds with heterocyclic P2′ groups as factor XIA inhibitors
CN103923080B (en) * 2014-04-04 2016-06-22 苏州景泓生物技术有限公司 A kind of method preparing antithrombotic reagent Eliquis
CN105085515B (en) * 2014-05-22 2019-02-01 华北制药股份有限公司 Hydrazide kind compound as coagulation factor xa inhibitors
US9938272B2 (en) 2014-05-22 2018-04-10 North China Pharmaceutical Company., Ltd. Hydrazine compound as blood coagulation factor Xa inhibitor
WO2015177801A1 (en) * 2014-05-23 2015-11-26 Symed Labs Limited Novel process for the preparation of a lactam-containing compound
DE102014108210A1 (en) 2014-06-11 2015-12-17 Dietrich Gulba rodenticide
HU231122B1 (en) 2014-08-06 2020-11-30 Egis Gyógyszergyár Zrt Process for the preparation of apixaban
CA2959987C (en) * 2014-09-02 2023-05-09 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Pyrazolo[3,4-c]pyridine compounds and their anti-thrombosis effect
CN104311555B (en) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 Pyrazolo piperidone compounds and composition thereof and purposes
CN104277040B (en) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 Containing acyl piperazine ketone substituent pyrazolo piperidone compounds and composition thereof and purposes
CN104311557B (en) * 2014-09-19 2016-01-06 广东东阳光药业有限公司 Containing diketone substituent pyrazolo piperidone compounds and composition thereof and purposes
CN104277041B (en) * 2014-09-19 2016-01-06 广东东阳光药业有限公司 Aromatic nucleus containing substituent methyl substituent pyrazolo piperidone compounds and composition thereof and purposes
CN104277039B (en) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 Contain the pyrazoles piperidone compounds and composition thereof and purposes that replace butynyl
CN104311541B (en) * 2014-09-19 2017-12-05 广东东阳光药业有限公司 Containing substituted pyrazole compound of ketone and combinations thereof and purposes
CN104327074B (en) * 2014-09-19 2016-01-06 广东东阳光药业有限公司 Containing lactan substituent pyrazolo piperidone compounds and composition thereof and purposes
NO2721243T3 (en) 2014-10-01 2018-10-20
HU230991B1 (en) 2014-11-19 2019-08-28 Egis Gyógyszergyár Zrt. Intermediate and process for the preparation of apixaban
US9603846B2 (en) 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
CN104513239B (en) * 2014-12-10 2017-08-22 沈阳药科大学 The ketone compounds of pyrazolo [3,4 c] pyridine 7 and its application
CN104530080B (en) * 2014-12-10 2017-01-11 广东东阳光药业有限公司 Oxazolidinone compounds and application thereof in drugs
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
CN104892601B (en) * 2015-06-09 2017-09-19 江苏中邦制药有限公司 A kind of preparation method of antithrombotic reagent Eliquis
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
WO2016203401A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
LT3307739T (en) 2015-06-15 2021-03-10 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2016205482A1 (en) 2015-06-19 2016-12-22 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
ES2871111T3 (en) 2015-07-29 2021-10-28 Bristol Myers Squibb Co Macrocyclic factor XIa inhibitors containing a non-aromatic P2 'group
ES2754599T3 (en) 2015-08-05 2020-04-20 Bristol Myers Squibb Co Novel substituted glycine-derived FXIa inhibitors
MY198346A (en) 2015-10-01 2023-08-28 Biocryst Pharm Inc Human plasma kallikrein inhibitors
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
EP3380083A1 (en) 2015-11-26 2018-10-03 Zentiva, K.S. Preparation of a drug form containing amorphous apixaban
KR20180117156A (en) 2016-03-02 2018-10-26 브리스톨-마이어스 스큅 컴퍼니 Diamide macrocycle with factor XIa inhibitory activity
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
TW201815787A (en) 2016-09-23 2018-05-01 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201825465A (en) 2016-09-23 2018-07-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201813963A (en) 2016-09-23 2018-04-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
EP3519399A1 (en) * 2016-10-03 2019-08-07 Sigilon Therapeutics, Inc. Compounds, devices, and uses thereof
CN107064367B (en) * 2017-04-20 2019-09-13 青岛理工大学 A method for the analysis and detection of four heterocyclic pesticides in environmental water samples
WO2019123194A1 (en) * 2017-12-20 2019-06-27 Pi Industries Ltd. Anthranilamides, their use as insecticide and processes for preparing the same.
AU2019339777B2 (en) 2018-09-12 2022-09-01 Novartis Ag Antiviral pyridopyrazinedione compounds
KR102188341B1 (en) 2018-10-24 2020-12-08 하나제약 주식회사 Method for Preparation of Apixaban
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
EP3753924A1 (en) * 2019-06-18 2020-12-23 AnaMar AB New tricyclic 5-ht2 antagonists
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
CA3164134A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US12606558B2 (en) 2020-04-09 2026-04-21 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of SARM1
WO2022115051A1 (en) 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Direct compression method for non-micronised apixaban formulations
WO2022115052A1 (en) 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Improved wet granulation processes for apixaban comprising formulations
SI4347031T1 (en) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US12214075B2 (en) 2021-10-27 2025-02-04 Pharma-Data Research And Development Single Member S.A. Apixaban suspension and preparation method
NL2029536B1 (en) 2021-10-27 2023-05-26 Pharma Data S A Apixaban suspension and preparation method
TW202425999A (en) * 2022-10-19 2024-07-01 英商卡爾維斯塔製藥有限公司 Enzyme inhibitors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340269A (en) 1964-09-08 1967-09-05 Ciba Geigy Corp 1-substituted 4-acyl-2, 3-dioxo-piperidine
US3365459A (en) 1964-09-08 1968-01-23 Ciba Geigy Corp Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
US3423414A (en) 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
WO1994020460A1 (en) 1993-03-11 1994-09-15 Smithkline Beecham Corporation Chemical compounds
RU2131876C1 (en) * 1993-07-06 1999-06-20 Пфайзер Инк. Bicyclic tetrahydropyrazolepyridines or their pharmaceutically acceptable salts, pharmaceutical composition, method of phosphodiesterase inhibition, method of patient treatment
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
PL319758A1 (en) 1994-10-20 1997-08-18 Pfizer Bicyclic tetrahydropyrasole pyridines and their application as medicines
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5939418A (en) 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
US5925635A (en) 1996-04-17 1999-07-20 Dupont Pharmaceuticals Company N-(amidinophenyl) cyclourea analogs as factor XA inhibitors
US6057342A (en) 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
CA2276034A1 (en) 1996-12-23 1998-07-02 Mimi Lifen Quan Oxygen or sulfur containing 5-membered heteroaromatics as factor xa inhibitors
US6548512B1 (en) 1996-12-23 2003-04-15 Bristol-Myers Squibb Pharma Company Nitrogen containing heteroaromatics as factor Xa inhibitors
CN1246847A (en) 1996-12-23 2000-03-08 杜邦药品公司 Nitrogen containing heteroaromatics as factor Xa inhibitors
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998057934A1 (en) 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS
KR20010013977A (en) 1997-06-19 2001-02-26 블레어 큐. 퍼거슨 Inhibitors of factor xa with a neutral p1 specificity group
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
EP1040108B1 (en) 1997-12-19 2004-02-25 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
IL136637A0 (en) 1997-12-22 2001-06-14 Du Pont Pharm Co Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
US6271237B1 (en) 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
DE69920888T2 (en) 1998-03-27 2006-02-02 Bristol-Myers Squibb Pharma Co. DISUBSTITUTED PYRAZOLINES AND TRIAZOLINES AS FACTOR XA INHIBITORS
WO2000001389A1 (en) 1998-07-06 2000-01-13 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6249205B1 (en) * 1998-11-20 2001-06-19 Steward, Inc. Surface mount inductor with flux gap and related fabrication methods
FR2787708B1 (en) * 1998-12-23 2002-09-13 Oreal DYEING PROCESS USING AN ACTIVE METHYLENE COMPOUND AND A COMPOUND CHOSEN FROM AN ALDEHYDE, A KETONE, A QUINONE AND A DERIVATIVE OF DI-IMINO-ISOINDOLINE OR 3-AMINO-ISOINDOLONE
WO2000038683A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
US6858616B2 (en) 1998-12-23 2005-02-22 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor Xa inhibitors
DE69921358T2 (en) 1998-12-23 2006-03-09 Bristol-Myers Squibb Pharma Co. NITROGENIC HETEROBICYCLES AS FACTOR XA HEMMER
WO2000059902A2 (en) 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company Aryl sulfonyls as factor xa inhibitors
DE19932813A1 (en) 1999-07-14 2001-01-18 Bayer Ag Substituted phenyluracile
JP2004507439A (en) 1999-07-16 2004-03-11 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー Nitrogen-containing heterobicyclic compounds as factor Xa inhibitors
JP2003509412A (en) 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Factor Xa inhibitor
WO2001032628A1 (en) 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
US6407256B1 (en) 1999-11-03 2002-06-18 Bristol Myers Squibb Co Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
ES2170037T3 (en) * 2000-05-19 2004-04-01 Usm Holding Ag WIRED IN A MODULAR FURNITURE SYSTEM.
DE10112768A1 (en) * 2001-03-16 2002-09-19 Merck Patent Gmbh New heterocyclic-substituted phenyl compounds, are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, restenosis or tumor diseases
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
US6960595B2 (en) 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
CA2441772A1 (en) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-¬3,4-c|-pyridin-7-ones as factor xa inhibitors
CA2444571A1 (en) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1, 4, 5, 6-tetrahydropyrazolo-¬3, 4-c|-pyridin-7-ones as factor xa inhi bitors
AU2002330911B2 (en) 2001-07-20 2007-01-04 Aderant Compulaw, Llc Method and apparatus for management of court schedules
CA2461202C (en) 2001-09-21 2011-07-12 Donald Pinto Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200738672A (en) 2001-12-10 2007-10-16 Bristol Myers Squibb Co Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
US7312214B2 (en) 2002-05-10 2007-12-25 Bristol-Myers Squibb Company 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
US6927187B2 (en) 2003-07-11 2005-08-09 Exxonmobil Chemical Patents Inc. Synthesis of silicoaluminophosphates

Also Published As

Publication number Publication date
US20050267097A1 (en) 2005-12-01
NO2011021I2 (en) 2012-06-25
HK1061973A1 (en) 2004-10-15
EP2105436A1 (en) 2009-09-30
RU2008134413A (en) 2010-02-27
FR11C0042I2 (en) 2013-01-11
UA78232C2 (en) 2007-03-15
US20110212930A1 (en) 2011-09-01
DE122011100050I1 (en) 2012-03-15
CL2008002717A1 (en) 2009-01-09
HUS1300014I1 (en) 2017-10-30
IS7184A (en) 2004-03-16
LTPA2011012I1 (en) 2012-07-25
DE60233335D1 (en) 2009-09-24
CN102617567A (en) 2012-08-01
EP2105436B1 (en) 2012-02-08
HRP20040280B1 (en) 2013-09-30
ZA200402184B (en) 2005-07-27
MY137830A (en) 2009-03-31
AR037092A1 (en) 2004-10-20
NO2011021I1 (en) 2011-09-26
US20120201816A1 (en) 2012-08-09
MXPA04002526A (en) 2004-05-31
HRP20080382A2 (en) 2008-12-31
HUP0402463A2 (en) 2005-04-28
IL160693A (en) 2011-06-30
PL204653B1 (en) 2010-01-29
CY2011016I2 (en) 2017-11-14
MEP58108A (en) 2011-05-10
NO20041163L (en) 2004-05-03
IL160693A0 (en) 2004-08-31
US8188120B2 (en) 2012-05-29
US8470854B2 (en) 2013-06-25
BR0212726A (en) 2004-08-03
HU228195B1 (en) 2013-01-28
BRPI0212726B8 (en) 2021-05-25
US7960411B2 (en) 2011-06-14
PT1427415E (en) 2009-10-29
ATE439360T1 (en) 2009-08-15
US20140113892A1 (en) 2014-04-24
IS8803A (en) 2009-02-26
US20080090807A1 (en) 2008-04-17
CY2011016I1 (en) 2017-11-14
AU2008207537B8 (en) 2011-12-08
ME00090B (en) 2010-10-10
PL204263B1 (en) 2009-12-31
US20180244673A1 (en) 2018-08-30
MEP8708A (en) 2010-06-10
NZ531616A (en) 2006-12-22
KR20040041167A (en) 2004-05-14
EP1427415A4 (en) 2005-11-02
WO2003026652A1 (en) 2003-04-03
US7691846B2 (en) 2010-04-06
CN101357914A (en) 2009-02-04
US20150210691A1 (en) 2015-07-30
AU2008207537A1 (en) 2008-09-18
BRPI0212726B1 (en) 2015-11-24
FR11C0042I1 (en) 2011-04-11
JP2005507889A (en) 2005-03-24
AR067965A2 (en) 2009-10-28
HRP20040280A2 (en) 2007-09-30
HUP0402463A3 (en) 2011-07-28
AU2008207537B2 (en) 2010-11-04
CN104744461A (en) 2015-07-01
ATE544750T1 (en) 2012-02-15
RS20040227A (en) 2006-12-15
JP2009079059A (en) 2009-04-16
PL373299A1 (en) 2005-08-22
NO2023030I1 (en) 2023-08-17
CN110894196A (en) 2020-03-20
IS2824B (en) 2013-03-15
CN1578660B (en) 2010-11-24
IS3006B (en) 2018-11-15
NO20083684L (en) 2004-05-03
LU91888I2 (en) 2011-12-19
US7338963B2 (en) 2008-03-04
EP1427415B1 (en) 2009-08-12
US7531535B2 (en) 2009-05-12
CY1110509T1 (en) 2015-04-29
CH1427415H1 (en) 2023-12-21
US20100119510A1 (en) 2010-05-13
US20200140436A1 (en) 2020-05-07
BE2011C034I2 (en) 2021-11-22
US20090176758A1 (en) 2009-07-09
JP4249621B2 (en) 2009-04-02
JP4889705B2 (en) 2012-03-07
KR100908176B1 (en) 2009-07-16
IL203533A (en) 2011-12-29
RU2004112191A (en) 2005-10-10
RS51444B (en) 2011-04-30
AU2002341693B2 (en) 2008-05-29
KR20080075927A (en) 2008-08-19
CA2461202C (en) 2011-07-12
NO328558B1 (en) 2010-03-22
US20170050964A1 (en) 2017-02-23
EP1427415A1 (en) 2004-06-16
RU2345993C2 (en) 2009-02-10
CO5560567A2 (en) 2005-09-30
RS20080517A (en) 2009-07-15
DK1427415T3 (en) 2009-11-23
CA2726702A1 (en) 2003-04-03
SI1427415T1 (en) 2009-12-31
CN1578660A (en) 2005-02-09
US9975891B2 (en) 2018-05-22
KR100909141B1 (en) 2009-07-23
ES2329881T3 (en) 2009-12-02
LU91888I9 (en) 2019-01-03
ME00384B (en) 2011-05-10
GEP20074098B (en) 2007-05-10
LTC1427415I2 (en) 2023-10-10

Similar Documents

Publication Publication Date Title
CA2461202A1 (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AU2020202167A1 (en) Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
US6995172B2 (en) Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
JP2009525285A5 (en)
US7696352B2 (en) Factor Xa inhibitors
JP4870562B2 (en) Sulfonamide derivatives for the treatment of diabetes
RU2007117913A (en) 2, 6-SUBSTITUTED-4-MONO-SUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDINE D2 RECEPTOR ANTAGONISTS
CA2450007A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
RU2016102137A (en) PRIMARY CARBOXAMIDES AS BIK INHIBITORS
HRP20141190T1 (en) Di-substituted pyridine derivatives as anticancers
JP2020521730A5 (en)
JP2006500348A5 (en)
JP2009533427A5 (en)
CA2510519A1 (en) Condensed furan compounds
RU2013133881A (en) 2-ARYLIMIDAZO [1,2-b] Pyridazine Derivatives, 2-Phenylimidazo [1,2-a] Pyridine and 2-Phenylimidazo [1,2-a] Pyrazine Derivatives
JP2005500288A5 (en)
JP2007513915A5 (en)
JP2004532227A5 (en)
JP2008516902A5 (en)
RU2007116431A (en) ALKYLATED PYRIMIDINE DERIVATIVES AS 11-BETA INHIBITORS FOR DIABETES
JP2019521153A5 (en)
AU2006265653A1 (en) Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer
JP4564792B2 (en) Treatment agent for thrombus / embolism

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220920